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Abstract 
 
In the last decade, important progress has been made in the development of 
genetically encoded biosensors that can be used to detect and study second 
messengers like cyclic 3’-5’ guanosine monophosphate (cGMP) in cells or living 
organisms. Recently generated transgenic mice that express cGi-type cGMP 
biosensors show a significant potential for research on this molecule and to study its 
spatiotemporal dynamics and a possible subcellular compartmentalization of its 
signaling pathways. In the current study, analysis of cGMP signals based on 
fluorescence resonance energy transfer (FRET), was performed in vascular smooth 
muscle cells (VSMCs) isolated from the murine aorta of transgenic, cGi-expressing 
mice. FRET cGMP biosensors located either in the cytosol (cGi500) or targeted to 
the plasma membrane (mcGi500) were tested and compared, upon application of 
special cGMP-elevating compounds like natriuretic peptides and the nitric oxide 
donor DEA/NO. VSMCs expressing either sensor, demonstrate different responses 
after exposure to cGMP-elevating agents that were applied either in constant or 
increasing concentrations. Responses showed different intensities, ranging from 
weak to strong cGMP transients. Importantly, differences were found between 
cGi500 and mcGi500 biosensors, in regard with responses induced after application 
of C-type natriuretic peptide, whereas only slight dissimilarities were observed after 
application of DEA/NO.  
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Περίληψη 
Την τελευταία δεκαετία, έχει παρουσιασθεί σημαντική πρόοδος στην ανάπτυξη 
βιοαισθητήρων FRET εκφραζόμενων σε ζωντανούς οργανισμούς, ιστούς και 
κύτταρα με στόχο την ανίχνευση και τη μελέτη της κυκλικής 3’-5’-μονοφωσφορικής 
γουανοσίνης (cGMP). Διαγονιδιακά ποντίκια που εκφράζουν τέτοιους 
βιοαισθητήρες επιδεικνύουν ιδιαίτερη χρησιμότητα για τη μελέτη του μορίου αυτού, 
σε ό,τι αφορά τη χωρο-χρονική δυναμική και τον υποκυτταρικό εντοπισμό των 
σινιάλων του. Στην παρούσα μελέτη, έγινε παρακολούθηση των σημάτων cGMP σε 
αγγειακά λεία μυικά κύτταρα αορτής ποντικού έπειτα από χορήγηση ειδικών 
ενώσεων (ANP, CNP & DEA/NO), ενώ παράλληλα έγινε δοκιμή και σύγκριση 
μεταξύ βιοαισθητήρων FRET που εντοπίζονται κατά βάση στο κυτοσόλιο (cGi500) 
και στην κυτταροπλασματική μεμβράνη (mcGi500). Διαπιστώθηκε ότι τα αορτικά 
λεία μυικά κύτταρα παρουσιάζουν διαφορική συμπεριφορά ύστερα από εφαρμογή 
διαφόρων cGMP-επαγόμενων ουσιών, είτε σε ίδιες ή αυξανόμενες συγκεντρώσεις 
και πως οι προκαλούμενες αποκρίσεις αυτών μπορεί να παρουσιάζουν απών, 
ασθενή, ήπιο ή έντονο χαρακτήρα. Επιπλέον, βρέθηκαν διαφορές αναμεταξύ των 
δύο βιοαισθητήρων σχετικά με τη χορήγηση C-τύπου νατριουρητικού πεπτιδίου 
(CNP), αλλά μικρές μονάχα ανομοιότητες παρατηρήθηκαν αναφορικά με 
αποκρίσεις έπειτα από χορήγηση μορίου-δότη του μονοξειδίου του αζώτου (DEA/
NO).  
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1 Introduction 
1.1 Cyclic GMP 
 
Cyclic guanosine 3′-5′ monophosphate (cGMP) is an important intracellular second 
messenger initially identified in rat urine in 1963 (Ashman, Lipton et al. 1963). It 
derives from guanosine-5'-triphosphate (GTP) which is an essential molecule for the 
synthesis of RNA and DNA. cGMP synthesis is induced by nitric oxide (NO) via NO-
sensitive enzymes called soluble guanylyl cyclases (sGCs) which exist in two 
isoforms (sGC-1 and sGC-2) (Russwurm, Koesling 2002). Moreover, cGMP can also 
be produced by stimulation with peptide hormone factors called natriuretic peptides 
through the particulate guanylyl cyclases (pGCs), like GC-A and GC-B (Kuhn 2003). 
After the synthesis of cGMP, its fate is the following according to existent 
knowledge so far: the cGMP-dependent serine-threonine kinases, cGKI and  cGKII 
(also named PKG-I and -II ) mediate most of the known cGMP effects (Hofmann, Feil 
et al. 2006); for instance, cGKI, which is highly expressed in smooth muscle cells, is 
involved in smooth muscle relaxation (Surks 2007). Apart from this kinase, there are 
additional cGMP effectors like the cGMP-regulated phosphodiesterases (PDEs); 
these enzymes catalyze the hydrolysis of the 3P-phosphodiester bond of cGMP or 
cAMP to yield GMP or AMP, respectively (Francis, Blount et al. 2011). Another target 
are the cyclic-nucleotide gated ion channels (CNG channels), a group of non-specific 
cation channels containing a carboxyl-terminal cyclic nucleotide-binding domain that 
is able to bind cAMP or cGMP (Biel and Michalakis 2009).  Finally, it has been 
demonstrated that cGMP can exit the intracellular compartment and relocate into the 
extracellular space through the active efflux transporter MRP4 and MRP5 (Sassi, 
Lipskaia et al. 2008). 
Experimental research has proved that cGMP and its descending effectors 
partake in many physiological and pathophysiological conditions. For example, it 
takes part in visual phototransduction, while it also contributes in the development of 
cardiovascular diseases, cancer and malaria which constitute the severest causes of 
death in modern human societies [(Chabre, Antonny et al. 1993); (Wolfertstetter et al. 
2013)]. cGMP is also involved in the onset of milder but not less common pathologies 
like asthma (Placeres-Uray, Gonzalez de Alfonzo et al. 2010). Consequently, the 
choice of many researchers to interpret the biochemical effects of this molecule 
seems justified. 
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1.2 Natriuretic Peptides and pGC Receptors 
 
The family of natriuretic peptides (NPs) consists of atrial natriuretic peptide (ANP), 
brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP). Dendroaspis 
natriuretic peptide (DNP) and renal natriuretic peptide (urodilantin) are considered to 
belong to the same family as well. NPs are polypeptides of a relatively small length 
(22-53 amino acids) which demonstrate structural similarities, even though they are 
evolutionarily distinct (Inoue, Naruse et al. 2003).   
ANP, BNP and CNP can regulate blood pressure and blood volume and are 
involved in modulating physiological processes such as fat metabolism, as well as 
pathophysiological phenomena like ventricular hypertrophy and pulmonary 
hypertension (Potter, Abbey-Hosch et al. 2006).  ANP along with BNP are 
synthesized in atrial cardiomyocytes and secreted into circulation in response to 
cardiac wall stretch. Thus, they exert important cardiovascular functions by acting as 
endocrine factors. By contrast, CNP is mainly produced in vascular endothelial cells 
and chondrocytes, while it is also found in high concentrations in brain tissue [(Suga, 
Nakao et al. 1992); (Chusho, Tamura et al. 2001); (Sudoh, Minamino et al. 1990)]. It 
mediates the relaxation of vascular smooth muscle and inhibits the proliferation of 
VSMCs, a process that has been exploited to inhibit vascular pathogenesis [(Drewett, 
Fendly et al. 1995); (Furuya, Yoshida et al. 1991)]. CNP exhibits autocrine and 
paracrine regulatory functions in the cardiovascular system, as well as outside of it 
[(Sudoh, Minamino et al. 1990); (Suga, Nakao et al. 1992); (Hagiwara, Sakaguchi et 
al. 1994)]. 
Most of the known NPs are synthesized as pre-prohormones that undergo 
subsequent maturation, a process which leads to smaller forms containing a C-
terminus of 17 amino acids which form a disulfide ring structure (Potter, Abbey-
Hosch et al. 2006). The length of human preproANP is 151 amino acids and 
cleavage of the N-terminal signal sequence results in a precursor protein, proANP, of 
126 amino acids. This molecule is the predominant form to be stored in granules. 
After secretion stimulus, the biologically active form emerges after a second cleavage 
step, catalyzed by the protease corin, as a 28 amino acid C-terminal fragment (Yan, 
Wu et al. 2000).  
NPs are able to bind to three known transmembrane receptors: GC-A, GC-B, 
and the clearance (C) receptor (also known as NPR-C) that lacks guanylyl cyclase 
activity and participates in the metabolic clearance of the peptides (Fuller, Porter et 
al. 1988). 
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The main three members of NPs bind differentially to these receptors. GC-A 
is the receptor that mainly binds ANP and BNP, whereas GC-B represents the 
endogenous receptor for CNP [(Koller, Lowe et al. 1991); (Lopez, Garbers et al. 
1997)]. In contrast, the clearance receptor binds all three ligands with similar affinity 
[(Bennett, Bennett et al. 1991); (Potter, Abbey-Hosch et al. 2006)].  
GC-A and GC-B convert GTP into cGMP and pyrophosphate via their active 
catalytic domains. Thus, cGMP is the second messenger also in the signaling 
pathways of natriuretic peptides (Lucas, Pitari et al. 2000). The cGMP-generating 
receptors resemble growth factor receptor topology, containing an extracellular 
ligand-binding site (approximately 450 amino acids), a single hydrophobic 
membrane-spanning domain and an intracellular region of about 570 amino acids 
(Potter 2005). GC-A and GC-B receptors exist as homodimers, and they are inactive 
in the absence of ligand. Upon ligand binding, dimerization of the cyclase homology 
domain (CHD) follows, and this event is a prerequisite for the enhanced cyclase 
activity of these transmembrane receptors (Kuhn 2003). 
GC-A mRNA is predominantly found in kidney, adrenal, vascular, pituitary and 
fat tissue. GC-B mRNA is observed also in above mentioned tissues and additional 
expression was reported, e.g. in chondrocytes [(Lucas, Pitari et al. 2000); (Potter, 
Abbey-Hosch et al. 2006)]. The clearance receptor is found to be localized to atrial, 
kidney and venous tissue, as well as to smooth muscle cells and endothelial cells of 
the aorta [(Fuller, Porter et al. 1988); (Porter, Arfsten et al. 1990); (Nagase, Katafuchi 
et al. 1997)]. 
 
1.3 Nitric Oxide and the sGC Receptor 
 
NO is a significant signaling molecule produced by the enzyme NO synthase (NOS) 
from L-arginine and oxygen. In eukaryotic NO signaling, the initial event involves 
calcium increase, followed by binding of a calcium/calmodulin complex to NOS, 
which induces the activation of the enzyme. NOS enzyme exists in three isoforms: 
endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS) 
[(Forstermann, Schmidt et al. 1991); (Alderton, Cooper et al. 2001)]. NO can diffuse 
freely across cell membranes alleviating the need for a transport system. 
Furthermore, it can exit a cell in which it is produced and enter neighboring cells. 
Outstanding example of this phenomenon is the diffusion of NO from endothelial cells 
to aortic VSMCs. Several chemical modifications have been linked to the actions 
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exerted by NO. For instance, S-nitration which is a post-translational modification 
involving the oxidative addition of NO to a thiol of proteins, induced by NO-derived 
reactive nitrogen oxide species (RNOS), such as peroxynitrite (ONOO-) and nitrogen 
dioxide (NO2) [(Eiserich, Hristova et al. 1998); (Schopfer, Baker et al. 2003); (Radi 
2004)]. Additionally, a protein modification called S-guanylation occurs as well. This 
post-translational mechanism is based on the adduct formation of electrophilic 8-
nitro-cGMP which is generated from NO, with sulfhydryl groups of cysteine (Sawa, 
Zaki et al. 2007). The meaning of this phenomenon in vivo is not yet fully elucidated. 
At a low, non-toxic concentration, the electronic structure of NO makes it also an 
excellent ligand for heme.  
Thus, NO binds to sGC which is a histidine-ligated hemoprotein and is the 
only proven NO receptor (Derbyshire and Marletta 2012). sGC is heterodimeric in 
structure, and is composed of two subunits; α and β. As soon as NO binds to the 
heme of sGC, the enzyme is activated. The intracellular level of cGMP is therefore 
increased and signals are transmitted to its downstream targets.  The sGC/Fe+2/NO 
complex and the second messenger cGMP contribute to many signal transduction 
events, most notably in the cardiovascular system (e.g. in the regulation of vascular 
tone and platelet function), as well as in the nervous system (e.g. in 
neurotransmission) (Derbyshire and Marletta 2012).  
1.4 Regulation of the sGC, GC-A, and GC-B Receptors 
 
In GC-A and GC-B receptors, there can exist three main states of receptor activity: 
basal, active, and desensitized (Potter, Abbey-Hosch et al. 2006). In the basal state 
the enzymatic activity is repressed. Upon ligand binding, a conformational change is 
induced, bringing together the juxtamembrane regions of the receptor extracellular 
domain (Labrecque, Mc Nicoll et al. 1999). This signal is thereafter transduced 
across the membrane and relieves the repression of the kinase homology domain 
(KHD) on the catalytic domain. Thus, the latter is allowed to dimerize, exposing two 
active sites on each dimer (Potter, Abbey-Hosch et al. 2006). 
In their basal state and in the absence of ligands, GC-A and GC-B are highly 
phosphorylated, and prolonged exposure of receptors to NPs, induces reduction in 
receptor phosphate content that is correlated with reduction in NP-dependent 
stimulation of GC activity [(Potter and Garbers 1992); (Koller, Lipari et al. 1993); 
(Potter 1998); (Joubert, Labrecque et al. 2001)]. It is important to note, that ANP-
dependent dephosphorylation results primarily from reduced phosphorylation, but not 
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from increased dephosphorylation (Joubert, Labrecque et al. 2001). Under basal 
conditions and as it was observed in mice, GC-A can be phosphorylated on four 
serines (S497, S502, S506, and S510) and two threonines (T500 and T513) within a 
17 amino acid stretch at the amino-terminal portion of its KHD (Potter, Abbey-Hosch 
et al. 2006). Five of these sites (three serines and two threonines) were identified in 
human GC-A as well (Schroter, Zahedi et al. 2010, Yoder, Stone et al. 2010). The 
substitution of four or more phosphorylation sites to alanine, yields a receptor that is 
unresponsive to NPs, indicating that phosphorylation of GC-A is required for its 
activation by ANP and BNP (Potter and Hunter 1998). The less impaired glutamate-
substituted version of GC-A though, has been reported to be resistant to ANP-
dependent inactivation in membrane or whole cell preparations, which is an 
additional evidence that supports the desensitization by dephosphorylation model 
[(Potter and Hunter 1998); (Bryan and Potter 2002)].  
GC-B has the same overall topology as the GC-A receptor. GC-B can be 
phosphorylated on two threonines (T513, T516) and four serines (S518, S523, S487 
and S526). These phosphorylation sites were identified in rat and human GC-B 
[(Potter and Hunter 1998); (Yoder, Stone et al. 2010)]. Similarly to GC-A, mutating 
any of these amino acids to alanine or glutamate, reduces  NP-dependent GC activity 
(Yoder, Stone et al. 2010).  
Apart from NPs, there are also other molecules that regulate the activity of 
these receptors. For instance, protein kinase C (PKC) activators are found to be 
involved in the dephosphorylation and desensitization of GC-B, but in a different 
fashion than the NP-dependent dephosphorylation (Potter and Hunter 2000). 
Furthermore, agents or conditions that elevate intracellular calcium concentrations 
can cause reduced phosphorylation of GC-B [(Potthast, Abbey-Hosch et al. 2004); 
(Abbey-Hosch, Smirnov et al. 2005)]. On the other hand, ATP has been found to 
positively regulate the GC-A and GC-B receptors in vitro [(Foster and Garbers 1998); 
(Abbey-Hosch, Smirnov et al. 2005)]. 
Apart from the mechanisms mentioned above, there are also other regulating 
events associated with the control of the abundance of receptors at the cell surface. 
Receptor degradation or receptor internalization after ligand binding is a 
characteristic example (Flora and Potter 2010). Other mechanisms that influence 
receptor activity are the control of local ligand availability by sequestrating NPs via 
the clearance receptor or by ligand degradation through the insulin-degrading 
enzyme [(Matsukawa, Grzesik et al. 1999); (Ralat, Guo et al. 2011)].  
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As far as NO and sGC are concerned, maximal sGC activation gradually 
decreases after repetitive NO exposure, and this process refers to the desensitization 
of sGC (Bellamy, Wood et al. 2000). There is evidence which supports that S-
nitrosylation contributes to sGC desensitization [(Sayed, Baskaran et al. 2007); 
(Sayed, Kim et al. 2008)]. There are two different sGC/NO states which occur in vitro 
after NO binding, and there exist two models: the model of the dissociation of NO 
and the deactivation of NO-stimulated sGC (Derbyshire and Marletta 2012). NO 
dissociation from the heme of sGC is slow, whereas the deactivation of sGC/Fe+2/NO 
complex is rapid, considering in vitro measurements. Therefore, NO-dependent 
deactivated sGC enzymes differ from unligated sGC species derived from the 
dissociation of NO from the heme and it has been suggested that two molecules of 
NO are able to bind to sGC. The importance of the two different sGC/NO states and 
the mechanism of sGC activation in vivo remain elusive. 
1.5 Aorta and cardiovascular system 
1.5.1 Anatomy and main function of the aorta 
The aorta constitutes the main blood vessel of the body and is divided into three 
anatomical parts: the ascending, the descending, and the abdominal aorta (De Graaf, 
1998; Tortora 1994). The ascending aorta begins at the left ventricle of the heart and 
rises up in the front of the chest towards the top of the body. At that level, it takes a 
hairpin turn which is called “aortic arch”, towards the back of the body. From the 
aortic arch, the descending aorta progresses at the spine down to the chest, through 
the thoracic diaphragm into the abdomen. Opposite the lower border of the fourth 
lumbar vertebra, the abdominal aorta is separated into two blood vessels, the 
common iliac arteries and a smaller vessel, the median sacral artery (Putz, Pabst 
2006). 
The aorta distributes oxygenated blood to all parts of the body (Waschke 
2011). The ascending aorta supplies the coronary arteries which provide blood to the 
heart itself. The aortic arch emits all important branches to the head, brain, and arms. 
The descending aorta sends branches to each costal. The abdominal aorta gives off 
branches to liver, intestines, kidneys, and other important internal organs. Finally, 
each of the terminal branches of the abdominal aorta goes to one of the legs.  
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Like all arteries, the aortic wall is composed of three layers: the intima, the 
media, and the adventitia. The intima is the innermost layer which constitutes a 
single layer of endothelial cells which align according to the flow, resting on a sub-
endothelial layer of elastin and collagen which anchors to the internal elastic lamina 
(Rhodin 1979).  The internal elastic lamina is a membrane that separates the intima 
from the media and consists of collagen type IV, fibronectin, and laminin. It acts as a 
cushion that allows bending and changes in diameter associated with changes in 
blood pressure (Silver et al. 1989). The media is the middle layer which consists of 
smooth muscle and elastic fibers. This structure allows the aorta to contract and relax 
through a complete cardiac cycle. Finally, the adventitia which is the outer layer, 
provides additional support and structure to the aorta. 
1.5.2 Human and mouse aorta 
The hemodynamics of human and mouse aorta has been compared and contrasted 
by many researchers in recent years to investigate whether it is indeed purposeful to 
study the mouse as a model for vascular physiology and diseases in human (Suo, 
Ferrara et al. 2007, Trachet, Swillens et al. 2009, Casteleyn, Trachet et al. 2010). 
Evidence demonstrates that the topography of the murine and human hearts 
and the branching patterns of their aortic arches present many analogies (Casteleyn, 
Trachet et al. 2010). For instance, both in mice and humans, the initial segment of 
the aorta is sigmoidally curved. Moreover, a non-planar geometry of the aortic arch is 
present in both species. The aortic arches of mice and older men seem anyhow, to 
share most similarities. The ascending and descending aorta of mice are not 
positioned in a single vertical plane (non-planar aortic geometry). This characteristic 
configuration is also present in humans, albeit least pronounced in younger men. 
However in mice, the transition between both aortic segments is more fluent and the 
aortic arch is positioned more transversely in the thorax (Casteleyn, Trachet et al. 
2010). 
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1.6 Vascular Smooth Muscle Cells (VSMCs) from the aorta 
1.6.1 General characteristics 
 
Vascular smooth muscle contracts or relaxes to change the volume of blood vessels, 
as well as the local blood pressure, a mechanism that is responsible for the 
redistribution of blood within the body to areas where it is needed, such as areas with 
temporarily enhanced oxygen consumption. Smooth muscle relaxation has been 
found to be induced via the NO/cGMP signaling pathway and one major effector 
implicated in this procedure, is the cGKIα isoform (Feil, Gappa et. al 2002). 
VSMCs contribute to the structural integrity of the blood vessels and their 
primary function is to regulate the diameter of the blood vessels in response to 
physiological stimuli (Metz, Patterson et al. 2012). Pathologically, excessive 
vasoconstriction results in hypertension, while excessive vasodilation results in 
hypotension. 
It has been established that VSMC phenotype is characterized by a dynamic 
nature and heterogeneity in vivo (Rensen, Doevendans et al. 2007). These 
phenotypes have been termed “contractile” and “synthetic” (figure 1.1), based on 
their primary functions of contraction or synthesis of extracellular matrix (ECM) 
proteins, respectively (Miano 2003). The contractile state is what is considered to be 
the primary state of VSMCs in a healthy aorta, while synthetic phenotypes have been 
observed in vivo during development, in response to injury followed by tissue repair, 
and in inflammatory response within the microenvironment of an atherosclerotic 
lesion (Louis and Zahradka 2010).    
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Figure 1.1. Characteristics of VSMCs in the synthetic and contractile phenotypic state. 
Adopted from Rensen, S. S., et al. (2007) "Regulation and characteristics of vascular smooth 
muscle cell phenotypic diversity." Neth Heart J 15(3): 100-108. 
1.6.2 Role of VSMCs in the onset of atherosclerosis 
 
Atherosclerosis literally stands for the thickening of an artery wall and this is a 
progressive process responsible for most heart diseases. This disease state is 
considered as the leading cause of death for advanced-aged adults in most 
developed countries (Weber and Noels 2011). Different cell types partake in the 
onset of this condition, such as macrophages, white blood cells, monocytes, 
endothelial cells, and platelets [(Ross 1999); (Galkina and Ley 2009)]. It has been 
found that aortic VSMCs contribute to this complex and time-requiring condition as 
well: Calcification, apoptosis, proliferation and migration from the media to intima are 
key events which play important roles in its pathogenesis (Rudijanto 2007).  
Interestingly, cyclic GMP has been found to be implicated in all those crucial 
events [(Kanno, Into et al. 2008); (Sarkar, Meinberg et al. 1996); (von der Leyen, 
Gibbons et al. 1995); (Pollman, Yamada et al. 1996)]. However, there are 
contradictory results in the literature regarding some aspects, such as proliferation 
[(Boerth, Dey et al. 1997), (Hassid, Arabshahi et al. 1994)]. This fact implies the 
possibility that VSMCs may respond differently to the same stimuli or that there are 
regulatory mechanisms that are not yet fully understood or remain to be identified. 
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1.7 Transgenic mice and the Cre/lox recombination system 
 
Transgenic animals are extensively used in research to study in vivo gene function in 
respect with development and pathogenesis. It is achievable to evaluate therapeutic 
approaches in models of human disease and to investigate progression of diseases 
in a manner which is hardly feasible to study in human patients.  
A transgenic animal can be generated by several methods which include 
microinjection of a DNA fragment into the pro-nucleus, embryonic stem cell 
manipulation and injection, sperm-mediated transgenesis, and viral infection of pre-
implanted embryos (Tian, Wang 2007). The microinjection method is one of the most 
widely used approaches so far. 
The mouse (Mus musculus) is one of the most utilized organisms for 
research. Transgenesis in mice is a widely used approach to generate models of 
human disease. Transgenic mice offer the advantages of relatively low cost and a 
short gestation time which ranges from 18.5 to 21 days (Gama Sosa, De Gasperi et 
al. 2010). Additional advantages are the availability of genetically inbred strains and 
the relatively close evolutionary relationship of mice and humans. Moreover, a variety 
of technologies for introducing genetic modifications within specific loci (e.g. the 
ROSA26 locus), into the mouse genome is also available [(Gama Sosa, De Gasperi 
et al. 2010); (Casola 2010)]. Genetic modifications including deletions, mutations, 
inversions or translocations can be introduced using the gene targeting technology.  
One technology that permits inducible gene expression in specific tissues is 
the Cre/lox recombination system (Novak, Guo et al. 2000). Cre recombinase is a 
type I topoisomerase from P1 bacteriophage that catalyzes abscission and site-
specific recombination of DNA sequences between loxP sites (Hamilton and 
Abremski 1984). Recombination products are dependent on the location and relative 
orientation of the loxP sites: Two DNA segments containing single loxP sites will be 
fused, whilst DNA between such sites in the same orientation will be excised in 
circular form. Lastly, DNA between opposing loxP sites will be inverted with respect 
to the rest of the DNA. The reactions of recombination proceed via covalent 
recombinase-DNA intermediates with conservation of phosphodiester bond energy, 
and requires no DNA synthesis (Feil 2007).  
To introduce transgenes with loxP sites in the mouse genome, the technology 
of homologous recombination in ES cells is utilized [(Copeland, Jenkins et al. 2001); 
(Court, Sawitzke et al. 2002)]. The targeting construct is designed to have two loxP 
sites flanking one or more exons of the gene of interest and positioned in the 
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surrounding introns, so that they do not intervene with gene expression. In the 
construct, it is also included a loxP flanked stop cassette, to block ubiquitous 
transgene expression and to allow its expression only upon introduction of Cre 
recombinase. The mice which carry in their genome the loxP flanked version of the 
target gene are then crossed to mice selectively expressing Cre recombinase in 
specific tissues, generating descendants with permanent inactivation or activation of 
the respective gene based on the pattern of Cre expression. This pattern can be 
controlled by cell type-specific promoters. The Cre/lox system is the most useful and 
efficient tool for site-specific genome engineering in the mouse.   
 Gene knock-in strategies have been used to replace or mutate genes at a 
particular locus in a chromosome (Nilles and London 2007). The gene of interest can 
be labeled to clarify its expression pattern with a reporter gene such as GFP. In 
knock-in mice, reporters are expressed at the same time (age) and with the same 
tissue distribution as the native gene and are ideal for localizing gene expression. 
Importantly, replacement of a indigenous gene (e.g. prkg1) with a transgene by this 
targeting method has been used in the generation of cGMP FRET sensor knock-in 
mice (Thunemann, Wen et. al 2013). 
1.8 Biosensors of cGMP and FRET as a tool for studying living cell 
biochemistry 
 
The design of genetically encoded fluorescent biosensors for cGMP is a major 
technical achievement, as it allows real-time monitoring of cGMP signals in various 
types of living cells (Thunemann, Fomin et al. 2013). These biosensors are 
composed of variants of the green fluorescent protein (GFP), such as the yellow 
(YFP) and the cyan (CFP) fluorescent protein. Most of the recently designed sensor 
proteins detect cGMP by the principle of FRET. This biophysical phenomenon is 
based on the transfer of energy from an excited donor fluorophore (e.g. CFP) to an 
acceptor fluorophore (e.g. YFP) in a non-radiating fashion via long-range dipole-
dipole interactions (Förster, 1946). The donor and acceptor fluorophores must be in 
close proximity (2-6 nm) and in appropriate orientation in respect to each other. 
Furthermore, the donor’s emission spectrum must overlap with the acceptor’s 
excitation spectrum (Zaccolo 2004). Most FRET-based cGMP sensors consist of one 
or two cGMP-binding domains derived either from PDEs or from cGKs. Those 
elements are positioned between the fluorophores (CFP and YFP). Upon cGMP 
binding, a conformational change occurs to the structure of the sensor causing a 
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change in the distance and/or orientation of the fluorophores to each other. Thereby, 
cGMP binding can induce either an increase or a decrease of the FRET efficiency, 
depending on the type of sensor (Thunemann, Fomin et al. 2013). A change in FRET 
efficiency is depicted by calculating either the ratio of YFP over CFP emission or vice 
versa. In a cell expressing the sensor, the change of the CFP/YFP (or YFP/CFP) 
ratio therefore reflects the change of cGMP levels within the cell.  
The FRET-based cGi-type (for “cGMP indicator”) sensors designed by 
Russwurm and colleagues, are useful tools for cGMP imaging in intact cells and 
tissues of organisms [(Norris, Ratzan et. al 2009); (Thunemann, Wen et. al 2013); 
(Couto, Oda et. al 2013)]. Here, binding of cGMP to the binding site of this cGKI-
based biosensor induces a decrease of the FRET efficiency (Russwurm, 
Mullershausen et al. 2007). The FRET changes in cGi sensors are usually presented 
as donor-acceptor emission ratio (CFP/YFP), so that an increase in the cGMP 
concentration is illustrated by an increase in the emission ratio. The cGi-type sensors 
fulfill successfully the criteria of speed, amplitude, and reversibility of the FRET 
change as well as high sensitivity and selectivity to cGMP over cAMP (Russwurm, 
Mullershausen et al. 2007). 
Cyclic GMP can also be detected through another category of sensors, which 
is not FRET-based. Outstanding paradigm of this category is FlincG (for “fluorescent 
indicator of cGMP”). FlincGs are composed of a single circularly permutated EGFP 
(cpEGFP) fused to the regulatory domain of cGKI containing two cGMP-binding 
domains. Here, cGMP binding causes a detectable increase in GFP fluorescence 
intensity (Nausch, Ledoux et al. 2008). 
1.9 Goals 
 
Research on transgenic mice expressing the cytosolic cGi500 biosensor has been 
successfully performed and published (Thunemann, Wen et. al 2013). However, 
major research in relation with transgenic mice expressing the membrane-bound 
mcGi500 biosensor has not been done nor published. 
In this study, mcGi500 biosensor expressed in VSMCs isolated from R26-
CAG-mcGi500 mice was tested and utilized in direct comparison with cGi500 VSMCs 
isolated from R26-CAG-cGi500 mice (mixed culture). Basic aims of the study, were 
the characterization of the cell cultures by immunocytochemistry, as well as the 
verification of different localization between cGi500 and mcGi500. An important 
aspect of the current study was the investigation of possible differences between the 
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two FRET sensors in detecting cGMP spatiotemporal signals in response to cGMP-
modulating agents (e.g. CNP and DEA/NO). Furthermore, it was a matter of interest 
to study if there was diversity or homogeneity in responses associated with the 
exerted cGMP signals within the VSMCs from the aorta. Finally, it was under the 
scope of examination whether the R26-CAG-mT/mcGi500 allele could be converted 
to R26-CAG-mcGi500 in vitro, in SMCs and if the recombined SMCs could be 
monitored afterwards via FRET microscopy, in regard with cGMP responses. 
 
 
 
 
2 Materials and Methods 
Transgenic Mice (R26-CAG-cGi500 and R26-CAG-mcGi500) 
 
R26-CAG-cGi500 or R26-CAG-mcGi500 transgenic mice (species: Mus musculus; 
strain: 129Sv/C57BL6N) resided in a conventional mouse facility at 22oC and 50-60% 
humidity in a 12h/12h light/dark cycle with free access to standard rodent chow and 
tap water. Both male and female mice were used for experiments. Animal procedures 
were performed with supervision and were approved by the Regierungspräsidium 
Tübingen. 
2.1 Materials 
2.1.1 Reagents, Media, Solutions and Drug Substances 
 
 
Solutions for PCR-based Genotyping 
 
Proteinase K reaction mix 
prepare freshly 
Proteinase K (50 μg/μL, Roth) 1 μg/μL 1 μL 
10x Reaction Buffer S (Peqlab) 1x 5 μL 
H2O (milliQ) 44 μL 
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1×TBE 
adjust pH to 8.3, store at room temperature 
0.5 M Tris (Roth) 10.8 g 
0.5 mM H3BO3 (Roth) 5.5 g 
10 mM EDTA (Roth) 4 mL 
H2O (milliQ) 996 mL 
 
 
6×DNA loading dye 
store at 4oC 
40% Sucrose (Roth) 2 g 
0.125%  Bromophenol blue (Roth) 6 mg 
0.125%  Xylene cyanol (Roth) 6 mg 
1×TBE add 5 mL  
 
Solutions for Cell Culture 
 
Culture medium with 10% FBS 
store at 4oC 
DMEM with GlutaMAX (Invitrogen)  
FBS (Invitrogen, heat-inactivated) 10%, stored at -20oC   
100×Pen/Strep (Invitrogen) Penicillin: 10000 U/mL; Streptomycin: 100 μg/mL 
 
Serum-free culture medium 
store at 4oC for up to 2 months 
DMEM with GlutaMAX (Invitrogen)  
100×Pen/Strep (10000 U/mL / 100 μg/mL, Invitrogen) 100 U/ml / 1 μg/mL 
 
 
Phosphate-buffered saline (PBS) (Ca2+/Mg2+ free, pH 7.4) 
adjust pH to 7.4 with HCl or NaOH, aliquot, autoclave and store at room temperature 
135 mM NaCl 7.89 g/L   
3 mM KCl 0.22 g/L 
8 mM Na2HPO4 · 2 H2O 1.42 g/L 
2 mM KH2PO4 0.27 g/L 
H2O (double-distilled) 
 
1×Trypsin/EDTA 
store at 4oC 
10×Trypsin/EDTA (Invitrogen)  Trypsin: 5 g/L , EDTA: 2 g/L 
PBS 
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HTNC-Cre 
adjust pH to 7.4, store at -20oC 
440 μM HTNC-Cre in: 
50% Glycerol (Roth),  
1 M NaCl (Roth) and 
20 mM HEPES (Roth)  
 
 
All the solutions for cell culture besides HTNC-Cre were preheated to 37oC before 
use. Sterile conditions within the cell culture hood, were guaranteed by using 70% 
ethanol and UV radiation. Washing the bench with 70% ethanol is required before 
and during work under the cell culture hood in order to keep a contaminant-free 
environment. Pipettes with contents destined for cell culture were used only under 
sterile conditions (cell culture hood).  
 
 
Tools and solutions for FRET 
 
Inverted microscope (Axiovert 200 with 1.0/1.6x Optovar lens, Carl Zeiss). 
 
 
Fluorescence-grade objectives with 10x and 40x magnification (Plan NeoFluar 
10x/0.30; EC Plan NeoFluar 40x/1.30 Oil, Carl Zeiss). 
 
Computer-controlled light source (Oligochrome, TILL Photonics). 
 
FRET filter set: 445/20 nm CFP excitation filter and 470 nm dichroic mirror (AHF or 
Chroma Technology). 
 
Beam splitter (Micro-Imager DUAL-View, Photometrics) with 05-EM insert (516 nm 
dichroic mirror, 480/50 nm CFP and 535/40 nm YFP emission filters) placed between 
microscope and camera. 
 
Series 20 Chamber (Warner Instruments).  
 
Single Channel Heater Controller (TC-324B, Warner Instruments). 
 
SF-28 Sloflo In-line Solution Heater (Warner Instruments). 
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YFP filter set: 497/16 nm excitation filter, 516 nm dichroic mirror, 535/22 nm emission 
filter (AHF or Chroma Technology). 
 
Cooled electron-multiplying charged-coupled device (EM-CCD) camera (Retiga 
2000R, QImaging). 
 
Superfusion system: FPLC pump (Pharmacia P-500, GE Healthcare), FPLC injection 
valves (Pharmacia V-7, GE Healthcare), superfusion chamber (Warner Instruments), 
vacuum pump with adjustable vacuum, sample loops (e.g. 2, 5, 20 mL), tubing, 
connectors, hypodermic needles, and syringes. 
 
Image acquisition and online analysis software (Live Acquisition, TILL Photonics), 
image analysis software for offline analysis (Offline Analysis, TILL Photonics; 
ImageJ), data analysis software (Microsoft Excel, Microsoft; Origin, OriginLab Corp.). 
 
20% denatured ethanol. 
 
100 mM DEA/NO 
aliquots (50 μL), store at −20oC 
Dissolve 50 mg DEA/NO in 2.42 mL ice-cold 10 mM NaOH. 
 
 
100 mM ANP 
aliquot (50 μL), store at −20oC 
Dissolve 0.1 mg ANP (1-28, rat) in 0.327 mL ddH2O.  
 
100 mM CNP 
aliquot (50 μL), store at −20oC 
Dissolve 0.5 mg CNP (1-22, rat) in 2.275 mL ddH2O.  
 
 
Tyrode buffer 
adjust pH to 7.4, aliquot, autoclave, and store at room temperature 
140 mM NaCl (Roth) 8.18 g/L 
5 mM KCl (Roth) 0.373 g/L 
1.2 mM MgCl2 (Roth) 0.244 g/L  
2 mM CaCl2 (Roth) 0.9 g/L 
5 mM HEPES (Roth) 2.38 g/L 
H2O (milliQ) 
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Solutions for Immunostaining 
 
PBS-Formaldehyde 3.7% 
prepare freshly, chill on ice 
37% Formaldehyde (Roth) 1.5 mL 
PBS add 15 mL 
 
0.5% BSA-PBS 
prepare freshly 
BSA (Roth) 5 g/L 
PBS  
 
Serum-PBS 
prepare freshly 
5% Normal Goat Serum (Vector Laboratories) 0.5 mL 
BSA-PBS add 10 mL  
 
 
Hoechst 33258   
store in -20oC  
Hoechst 33258 (Sigma) 1μg/μL 
 
 
20% Triton-X 100  
store at room temperature 
Triton-X 100 (Roth) 20 mL 
H2O (double-distilled) add 80 mL 
 
 
80 % Glycerol  
microwave until dissolved, autoclave, store at room temperature 
Glycerol (Roth) 60 mL 
H2O (double-distilled) add 15 mL  
 
Solutions for subcellular fractionation 
 
Subcellular fractionation buffer: 
250 mM Sucrose (Roth) 
20 mM HEPES (Roth) (pH 7.4) 
10 mM KCl (Roth)       
1.5 mM MgCl2 (Roth)  
1 mM EDTA (Roth) 
1 mM EGTA (Roth) 
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The following are to be used at the time of use: 
 
1 mM DTT (Roth) 
100 mM PMSF (Roth) 
 
 
Protein Precipitation 
 
TCA 
store at room temperature 
100% (w/v) trichloroacetic acid (TCA) (Roth) 
Dissolve 5 g TCA into 3.5 mL H2O (milliQ). 
 
 
 
Solutions for SDS-PAGE  
 
4× Resolving gel buffer 
adjust pH to 8.8, store at 4 oC 
1.5 M Tris (Roth) 182 g/L 
0.4% SDS (Roth) 4 g/L 
H2O (milliQ) 
 
4× Stacking gel buffer 
adjust pH to 6.8, store at 4oC 
0.5 M Tris (Roth) 60.4 g/L 
0.4% SDS (Roth) 4 g/L 
H2O (milliQ) 
 
20% APS 
aliquot, store at -20oC, avoid long exposure to light 
20% APS (Roth) 2 g 
H2O (milliQ) add 10 mL 
 
 
10× SDS running buffer 
do not adjust pH, store at room temperature, prepare working solution as 1:10 
dilution, freshly 
0.25 M Tris (Roth) 30.2 g/L 
2 M Glycine (Roth) 144 g/L 
1% SDS (Roth) 10 g/L 
H2O (milliQ) 
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2.2 Methods 
2.2.1 Polymerase Chain Reaction (PCR) 
 
The polymerase chain reaction (PCR) is a highly sensitive method to amplify 
enzymatically defined DNA sequences in vitro (Saiki, Gelfand et al. 1988). In a cyclic 
process, the two strands of the DNA double helix are physically separated first by 
high temperature (95oC). After this initial step, and at lower temperatures, template- 
specific oligonucleotide primers hybridize (50-65oC). Then, at optimal working 
temperature (e.g. 72oC), a thermostable DNA polymerase such as Taq polymerase, 
elongates the primers in 5’-3’ direction. By repeating DNA melting, primer 
hybridization and DNA polymerization, the template DNA defined by the binding site 
of two primers, is amplified in an exponential fashion. 
PCR was used to determine the genotype of transgenic mice used for aortic 
VSMC preparation as described before (Feil, Valtcheva et al. 2009). DNA was 
isolated from the ear patch area of mice. Tissue was incubated with digestion mix (50 
μL for each sample) in the oven (55oC) overnight, along with proteinase K which is a 
broad-spectrum serine protease. The used primer pairs have been mentioned and 
given in detail in published work (Thunemann, Wen et. al 2013).  
 
2.2.2 Tissue Isolation  
 
VSMCs from the aorta, BSMCs and CSMCs were isolated from mice as previously 
described (Thunemann, Fomin et al. 2013). Transgenic mice that ubiquitously 
expressed cGi500 or mcGi500 biosensor, were sacrificed and used for tissue 
isolation. For VSMC preparation, four aortae had to be isolated for each sensor in 
order to acquire sufficient amount of VSMCs to be seeded in 24-well plates. The age 
of mice ranged from 1 to 4 months.  
Mice were sacrificed by inhalation of carbon dioxide. Using ice-cold PBS and 
working on ice are necessary procedures while working after the isolation of smooth 
muscle-rich tissues. The main reason for this is that the degradation should be as low 
as possible in a period of time. For VSMCs, surrounding fat and connective tissue 
were removed from the aorta. Then, tissues were cut into 5-mm pieces and 
incubated at 37oC for 45 minutes with papain (0.7 mg/mL), followed by 10-15 minutes 
with collagenase (1 mg/mL) and hyaluronidase (1 mg/mL); tissues were dissociated 
by pipetting through a 1000-μL pipette tip. The amount of wells and culture plates 
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was chosen according to the availability of viable cells, counted by trypan blue 
exclusion. Thereinafter, cells were suspended in culture medium (DMEM with 4.5 g/L 
glucose, 100 U/mL Penicillin, 100 μg/mL Streptomycin, 10% FBS) in 24-well plates 
and they were grown in an incubator (CO-170, Innova) at 37oC and in humidified 
atmosphere (94% air, 6% CO2), until the time of use.  
2.2.3 Cell culture 
 
2.2.3.1 Medium change 
 
Three days after the isolation of primary VSMCs, the cells in the 24-well plates were 
washed once or twice with 0.4 mL of PBS and afterwards 1 mL of fresh pre-warmed 
medium was added to each well. In a period of 3-4 days, the medium was changed 
and replaced by fresh one. 24 hours prior of FRET measurements or 
immunostaining, the medium was changed into serum-free as growth factors 
contained in the serum might interfere with cGMP signaling and with the phenotype 
of VSMCs. 
 
2.2.3.2 Passaging of VSMCs from the aorta 
  
VSMCs grown up to 90% of confluency were allowed to be passaged. Normally, the 
faster the cells grew the higher the ratio used for passaging. The ratios were in the 
range of 1:2 to 1:6. Passaged cells were distributed between wells using the same 
ratio. Cells should be passaged when they reach 70 to 90% confluency. Do not allow 
the cells to acquire 100% confluency as the capacity for exponential growth may be 
diminished.  
1. Aspirate medium from the cell culture well. 
2. Wash cells once by adding 100 μL/cm2 of pre-warmed (approx. 37oC) PBS, 
then aspirate PBS. 
3. Add 50 μL / cm2 of detachment enzyme (Trypsin / EDTA) to the wells. 
4. Incubate at 37oC until cells are rounded and start to detach. Check for cell 
detachment under the microscope. 
5. Tap carefully the culture well plate. 
6. Rinse the bottom of the culture well 2 to 3 times with the suspension to 
remove all cells and to separate them into a single cell suspension. 
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7. Stop the enzymatic reaction by adding 3x volume the amount of fresh pre-
warmed medium. 
8. Transfer cell suspension into a falcon tube. 
9. Centrifuge cells for 10 minutes, 1200 rpm at room temperature (Centrifuge 
5804 R, Eppendorf). 
10. Aspirate supernatant and resuspend the pellet in 1 to 2 mL medium. 
11. Seed viable cells with 4 x 103 / cm2. 
 
 2.2.4 Fluorescence Resonance Energy Transfer (FRET) 
 
The fluorescence resonance energy transfer (FRET) between two molecules (donor 
and acceptor) is a biophysical phenomenon first described by Förster in 1946. Today, 
it is mainly used in understanding various intracellular signaling entities as a part of 
biochemical research, as well as in drug discovery. In the process of FRET, initially a 
donor fluorophore absorbs the energy due to the excitation of incident light and 
transfer the excitation energy to a nearby chromophore, the acceptor. 
In this study, FRET was used to monitor cGMP in real-time, in living 
transgenic VSMCs, after applying specific substances. Cells were grown at 37oC and 
6% CO2, in cell culture medium (DMEM with 10% FBS) for 4 up to 14 days until 
FRET analysis. 
The followed protocol is the below: 
 
1. Select wells with cells having the appropriate morphology and confluency and 
place them in serum-free medium at least 24 hours prior any measurements. 
FBS that is present in serum contains constituents such as a variety of growth 
factors which some of them (e.g. fibroblast growth factor) could interfere with 
the cGMP signaling pathway and with the smooth muscle phenotype.  
2. Before starting measurements, set the light source on power at least 30 minutes 
prior and rinse the superfusion system with 20% denatured ethanol for 10 
minutes. After this washing step, rinse with the Tyrode Buffer solution for 10 
minutes. 
3. Degas the Tyrode with ultrasound for 5 minutes (Elma S 30 H).  
4. Open the computer application software (Live Acquisition software, TILL 
Photonics) and fix the camera alignment via a special microscopic slide 
(Photometrics).  
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5. Put silicon (GE Bayer) on the chamber (Warner Instruments), only close to the 
borders and wipe off the excess of it with a cotton bud. 
6. Transfer coverslip via a forceps and a needle (21 gauge), with the cells facing 
upside, into a tissue culture petri dish (35 x 10 mm, Cellstar) filled with 1.5 mL of 
pre-warmed Tyrode.  
7. Mount coverslip to the bottom of the small chamber (Series 20, Warner 
Instruments), with the cells facing to the inside of the chamber. 
8. Put firmly together the chamber with the magnets and then immediately add 500 
μL of Tyrode Buffer onto the coverslip to ensure cell vitality. 
9. To measure with 40x, select the appropriate lens and place on its top, a drop of 
oil (Immersol 518 F, Zeiss). 
10. Remove liquid from the lower part of the coverslip with a tissue paper (11 x 21 
cm, KimTech Science), so that any humidity would not mix with the oil drop.  
11. Transfer the chamber carefully into the stage and plug the cables that belong to 
the superfusion system and the FPLC pump. 
12. Allow flow of Tyrode (at 60 mL/h) into the chamber and be cautious for any 
possible leakage. Do not continue the experiment, until you establish a stabilized, 
constant flow by adjusting the vacuum and the level of the outlet needle. 
13. Attach carefully the lens to the middle of the coverslip.  
14. Excite coverslip with cells, with the appropriate wavelength in the respective filter 
(e.g. for YFP, 497/16 nm, 516 nm dichroic mirror) and look for an area with the 
favorable cells. 
Use half or below of the light power of the channel to avoid photo-oxidative stress 
as much as possible. 
15. Arrange the appropriate acquisition program settings: Binning, Cycle, Exposure 
Time etc. according to the needs of the experiment. 
16. Illustrate field of view from the microscope to the computer screen. 
17. Draw ROIs (Regions Of Interest), so that cells are marked and will be analyzed 
during the FRET measurement. 
18. Change to CFP filter (445/20 nm, 470 nm dichroic mirror) and start the 
measurement in the dark. 
Leave a slight light source on, so that you can perform accurately while you are 
doing the experiment. 
19. Change to lower levels of the parameters “Exposure Time” and “Cycle”, only if a 
noticeable change in the distribution of the biosensor (appearance of bright 
spots) is observed. 
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This is an indication of photo-bleaching effect which might critically interfere with 
the monitoring of the cell responses. Therefore in that case, new ROIs from 
another field of view must be obtained.   
20. Allow at least 60 frames (1 frame=5 s) to obtain a baseline which is necessary for 
further evaluation of the experiment. 
21. Dilute the drug of interest into a falcon tube with 3 mL of the same Tyrode in a 
particular concentration. 
Note that for preparation of DEA/NO, a special manipulation is needed (see 
below). 
22. After addition of the drug into the 2 mL-injection loop, turn manually from “Load” 
to “Inject”, and wait until a response (change between the CFP/YFP ratio) which 
would be represented normally as a formation of a curve.  
That indicates that cells do respond to the stimulus.  
23. Wait for the curve to return as close to the baseline, before any next drug 
application.  
Between the application of two different drugs, the injection loop is rinsed 
automatically with Tyrode. 
24. Repeat steps 21-23, according to the goals of each experiment. 
25. At the end of the experiment, disassemble carefully the chamber and use ddH2O 
onto tissue paper to clean the silicon grease. 
26. Rinse the superfusion system with 20% denatured ethanol at the end of series of 
experiments.  
The following drugs were used: ANP, CNP, DEA/NO, and stocks were kept on 
ice during measurements. ANP and CNP were diluted in 3 mL of Tyrode and used 
immediately. 1 μL of DEA/NO was diluted in a falcon tube with 1 mL of 10 mM NaOH 
and then from this solution the final dilution with the favorable concentration was 
achieved into another falcon tube containing 3 mL of Tyrode, according to the needs 
of each experiment. Note that the half-life of DEA/NO is approximately 12-15 minutes 
at 37oC, so a fresh drug dilution after this period of time is necessary. 
2.2.5 Evaluation of the data 
 
The evaluation of the FRET measurements is a crucial procedure, as it provides us 
with an amount of valuable information associated with the behavior of each cell to a 
specific stimulus that may exert cGMP production. Moreover, it is feasible to study 
the kinetics of each type of curve which represents the response to a drug application 
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and eventually, we can draw important conclusions about the biochemical events in 
the VSMC in respect to cGMP signaling. 
The recorded signals (CFP, YFP, CFP/YFP) were reported for each ROI 
using the program associated with the epifluorescence microscope. Those signals 
were normalized using the frames that preceded initial drug injection.  
The relative signal change (ΔR/R) was calculated according to following 
equation: 
ΔRR  = R(t)− RoRo . The R0 refers to the baseline normalization and R(t) represents the 
background-corrected CFP/YFP ratio: 
R0 = 
1n ∑ 𝑅𝑅(𝑡𝑡)𝑡𝑡1𝑡𝑡0  
 
R(t) = 
CFP ROI (t)− CFP bg (t)YFP ROI (t)− YFP bg (t) 
 
The index “(t)” indicates the time dependency of parameters. For baseline 
normalization, n ratio values obtained from t0 to t1 during the baseline period (i.e. 
from the start of the experiment to the first drug application) are averaged, leading to 
R0. With R0, ratio changes can be normalized to the baseline and denoted as ΔR/R. 
This was done automatically for all measurements via a self-made visual basic for 
application (VBA) script. Those ratios were plotted against time (s). 
Two methods were used to evaluate the obtained data. The first was 
performed manually via Excel and the second one automatically through Origin. As 
far as the Excel evaluation is concerned (figure 2.1), the following parameters were 
measured:   
1. “a” parameter 
This indicates the time from drug application until FRET response. The latter refers to 
the exact time point when a rising tendency starts and was verified whenever 
necessary (e.g. in cells with noise) from the elevation of the CFP signal intensity and 
the respective decrease of YFP. This fluctuation occurs upon cGMP binding to the 
cGKI-derived binding sites of sensors which leads to a conformational change and to 
reduced FRET efficiency between CFP and YFP. It is important to note that the time 
span from drug application until it reaches the stage with the coverslip is 19 seconds, 
as it was revealed by experiment in which fluorescein-coupled BSA was applied 
(Lehners, Chatzieleftheriadis).  
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2. “c” parameter 
This stands for the time from drug application until peak maximum. The peak 
maximum was determined by the highest point of the shaped curve that was also 
relatively close to the plateau of the cGMP transient. 
 3. “h” parameter 
This represents the height from baseline to peak maximum. The height of the 
baseline (ΔR/R) after normalization is normally equal with 1, but this does not occur 
always. Hence, in case of changes in baseline between applications, a new 
correction of ΔR/R from the baseline to peak maximum must be taken into 
consideration.   
 4. “e” parameter  
This indicates the time of “half-life” (t1/2) of the curve as it returns from plateau back to 
baseline. 
5 & 6. “r” and “s” parameters  
The “r” parameter depicts the rising time and it is given by the equation: r = c - a, 
while “s” parameter stands for the slope of the curve and it is calculated as: s = 
ℎ
𝑟𝑟
. 
 
Figure 2.1. Representation of the Excel evaluation strategy.  
The Origin evaluation included the “span” parameter, which is the height of 
the curve, and the “p” parameter which indicates the rise of the curve. Origin Pro 9 
h
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e
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s
r
a: time from drug application 
until response
c: time from drug application
until peak maximum
h: height from baseline to maximum
D 
r: the rising time (c - a) of the curve
s: the slope of the curve
e: the ‘‘half-life‘‘ of the curve
time (s)
ΔR/R
drug application 
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was used and the function that was utilized to fit the data, was the "Non-Linear Fitting 
Module". This module used a Levenberg-Marquardt algorithm for the approximation 
of the function to the data. 
 
2.2.6 Immunofluorescence staining of aortic VSMCs 
 
Immunocytochemistry and immunohistochemistry are methods to detect proteins in 
cells or tissue section(s), for analyzing their presence and distribution under the 
microscope. Immunofluorescence is a technique using fluorescent dye-labeled 
antibodies (Coons et. al 1942). Firstly, unlabeled primary antibodies bind specifically 
to their target proteins in the fixed and permeabilized cells, or tissue section(s). 
Fluorescent dye-labeled secondary antibodies are then used to visualize the target 
by binding specifically to the primary antibodies. By this method localization and co-
localization studies can be performed with subcellular resolution. In the present work, 
secondary antibodies labeled with the fluorescent dyes Alexa Fluor 488, 555 and 594 
were used (Table 2.1). The nuclei of the cells were stained to demonstrate that the 
cells were intact, and to estimate their number. For this purpose, the DNA-binding 
fluorescent dye Hoechst 33258 was used, which increases its fluorescence intensity 
when bound to DNA (Latt and Wohlleb 1975). BSA-PBS and Serum-PBS are used to 
reduce non-specific antibody binding by blocking hydrophobic binding sites 
(Renshaw 2007). The non-ionic detergent Triton X-100 enhances the penetration of 
the primary antibody by dissolving the lipid bilayer on cell membranes, nuclear 
membranes and organellar membranes. 
Aortic VSMCs that had grown on 13-mm coverslips in 24-well plates to a 
confluency of 80% and that were not destined for FRET measurements, were used 
for immunofluorescence. Immunofluorescence staining was done to investigate the 
presence and expression levels of α-smooth muscle actin in VSMCs and also to 
visualize the distribution of cGi500 and mcGi500 in this cell type. Respectively, the 
Cy3 channel was used for the detection of the secondary Alexa Fluor 555 and Alexa 
Fluor 594 antibody (Table 2.1), while the F340 channel for the detection of Hoechst 
33258.The performed protocol is the following: 
1. Wash cells on coverslips in 24-wells twice with 1 mL PBS. 
2. Fix cells in 1 mL ice-cold 3.7% formaldehyde in PBS solution on ice. 
3. Aspirate solution.  
4. Add 1 mL PBS immediately afterwards. 
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5. Add 2 mL BSA-PBS to a new 6-well plate, or 1.5 mL BSA-PBS to a new 12-
well plate, according to the number of coverslips that are about to be 
analyzed.  
(The protocol from this point and on will be referring to quantities as for 6-well 
plates.) 
6. Transfer coverslips to the new wells which contain BSA-PBS (from step 5) 
and incubate for 5 minutes or store coverslips at 4oC in the dark for up to 3 
days. 
7. Incubate for 15 minutes in 2 mL Serum-PBS with 0.2 % of Triton X-100. 
8. Wash once with 2 mL BSA-PBS. 
9. Place 70 μL primary antibody dilution (Table 2.1) in BSA-PBS onto parafilm. 
The parafilm should lay upon a humidified layer (e.g. wet tissue), so that the 
edges of the coverslip would not dry out. 
10. Place the cells upside-down onto the drop carefully, by avoiding air bubble 
formation. 
11. Incubate for 45 minutes at room temperature. 
It is also possible to incubate overnight, but this is not recommended, as 
drying might occur. 
12. Detach coverslip carefully from the parafilm. 
13. Transfer coverslips to a 6-well plate which contains 2 mL BSA-PBS with the 
cells facing upside. 
14. Wash once with 2 mL BSA-PBS. 
15. Place on parafilm a 70 μL drop of secondary antibody dilution containing 
1:1000 Hoechst 33258 stock solution, diluted altogether in BSA-PBS. 
16. Place the cells upside-down onto the drop carefully, by avoiding air bubble 
formation. 
17. Incubate for 30 minutes in the dark, at room temperature. 
18. Wash once with 2 mL BSA-PBS and twice with 2 mL PBS for 3 minutes. 
19. Place a 50 μL drop of mounting medium (Immu-Mount, Thermo Scientific) or 
alternatively 40 μL of 80% Glycerol onto a microscope slide (ca. 76 x 26 mm, 
Roth). 
In general, the mounting medium is preferred because it provides a better 
clarity in observations under the microscope. The disadvantage though is that 
it can dry easily and cause autofluorescence. In contrast, glycerol gives less 
autofluorescence, but it does not dry. 
20. Dip once the whole coverslip carefully for 1 second in H2O (milliQ), to wash 
away PBS salts. 
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21. Remove excessive liquid with a tissue paper and place coverslip slowly on 
the mounting medium or on the glycerol drop with the cells facing towards the 
microscope slide, by avoiding air bubble formation. 
22. Let the mounting medium dry overnight at room temperature in the dark or if 
you had selected glycerol, seal the edges of the coverslip carefully with a 
brush and nail polish, and wait for at least half an hour until it dries. 
23. Examine the microscopic slides under an epifluorescence microscope after 
exciting at the wavelength that is appropriate for the secondary antibody, and 
acquire at least four representative images from each coverslip for further 
analysis (e.g. counting the stained cells and total cell number by counting the 
number of nuclei). 
 
 
Table 2.1 Antibodies used in immunofluorescence. All antibody dilutions were prepared 
freshly. Primary antibody was diluted in BSA-PBS. Secondary antibody was diluted in BSA-
PBS plus 1:1000 Hoechst 33258 stock solution.  
 
Epitope Type Species Dilution Company/Order 
mouse-SMA 
(monoclonal) 
primary mouse 1:1000 Sigma  
(A2547) 
rabbit-GFP 
(polyclonal) 
primary rabbit 1:1000 Abcam  
(ab290) 
rabbit-IgG- 
Alexa Fluor 488 
secondary goat 1:500 Invitrogen 
(A11008) 
mouse-IgG- 
Alexa Fluor 555 
secondary goat 1:500 Invitrogen 
(A21424) 
rabbit-IgG- 
Alexa Fluor 594 
secondary goat 1:500 Invitrogen 
(A11012) 
 
2.2.7 Protein transduction of transgenic cells via HTNC 
 
Protein transduction is a process which relies on the inherent property of a small 
number of proteins and peptides of being able to transverse the cell membrane 
(Morris, Depollier et al. 2001). It has been demonstrated that small parts of these 
proteins (10–16 amino acids in length) are responsible for this phenomenon. Linking 
these domains covalently to compounds, antisense peptide nucleic acids, peptides, 
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or in-frame fusions with full-length proteins, enables them to enter the lipid bilayer of 
any cell type in a transporter and receptor-independent manner (Schwarze, Ho et al. 
1999). 
Recombinant Cre recombinase HTNC (His-TAT-NLS-Cre) is derived from E. coli 
bacteria carrying an engineered plasmid encoding Cre recombinase from 
bacteriophage P1 with additional N-terminal 6xHis tag, a TAT peptide and a NLS 
sequence. This cell-permeant Cre recombinase (HTNC) is considered the most 
effective protein in transduction and subsequent recombination compared to other 
forms of Cre recombinases (Peitz, Pfannkuche et al. 2002).  The efficiency of the 
protein transduction depends also on the cell confluency which should be at least 
80% as well as on the cell culture conditions which precede the procedure (see 
protocol; step 2).  The protocol mentioned below is as for each well of a 24-well plate: 
1. Wash once with 1 mL pre-warmed PBS. 
2. Incubate cells with serum-free medium (480 μL) 2-4 hours prior to HTNC 
transduction. 
This step can enhance the efficiency of the method.  
3. Dilute 2.8 μL of HTNC protein stock into 480 μL of serum-free medium in a 
1.5 mL Eppendorf tube. 
4. Tap the tube to mix well and centrifuge for 30 seconds to allow precipitation at 
the bottom. 
5. Remove serum-free medium from the well of interest. 
6. Take 450 μL of supernatant from the Eppendorf tube, avoiding precipitate 
aspiration, and add to the respective well. 
7. Place 24-well plate in the incubator for 8-20 hours. 
8. Wash twice with serum-free medium. 
Washing with PBS is not recommended as it could increase the stress that 
the cells are undergoing. 
9. Change medium into normal cell culture medium (DMEM with 10% FBS). 
This step can enhance the rate of proliferation and therefore may increase the 
number of the transduced cells.  
10.  Results are safe to be observed and obtained in the epifluorescent 
microscope 2-4 hours later.            
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2.2.8 Subcellular fractionation 
 
Subcellular fractionation is a method that provides the required means to analyze the 
properties and composition of purified cellular components. Subcellular fractionation 
by differential centrifugation was first described by De Duve and colleagues (De 
Duve, Pressman et al. 1955) and has subsequently been the method of choice for 
isolating cell organelles from various tissues and cultured cells.  
Subcellular fractionation was used for aortic VSMCs expressing either 
mcGi500 or cGi500 biosensor, and the ultimate goal was to investigate the 
distribution of each sensor in the cytosol, membrane, and nucleus. The performed 
protocol is the following (all centrifugations were done at 4oC):   
1. Remove medium from plates (145 x 20 mm, Cellstar) with cells and wash once 
with PBS. 
2. Lyse cells on plates using 500 μL of subcellular fractionation buffer. Scrape plates 
immediately with a cell scraper and place the homogenized cell extract in a 1.5 mL 
Eppendorf tube. 
3. Then pass lysate through a 26 Ga needle 10 times using a 1 mL syringe. 
4. Leave on ice for 20 minutes. 
5. Centrifuge at 3000 rpm for 5 minutes. The nuclear pellet should be washed once 
by adding 500 μL of fractionation buffer again. Disperse the pellet with a pipette and 
pass through a 26 G needle 10 times. 
6. Centrifuge again at 3000 rpm for 15 minutes. Remove the wash buffer, and 
resuspend the nuclear pellet in the nuclear buffer (standard lysis buffer with 10% 
glycerol and 0.1% SDS added). Sonicate nuclear pellet briefly (for 3 seconds) on ice. 
7. Remove supernatant and place it in a fresh 1.5 mL Eppendorf tube. 
8. Centrifuge the supernatant again at 8000 rpm. Remove the supernatant again. 
This is the cytosolic and membranic fraction. 
9. For a membranic fraction: centrifuge the supernatant in an ultracentrifuge 
(Beckman TL-100 Ultracentrifuge) in a special Eppendorf tube (9.5 x 38 mm, 
Microfuge Tube Polyallomer). Centrifuge at 41,000 rpm for 1 hour. Remove the 
cytosolic fraction as supernatant and place it in a fresh, normal 1.5 mL Eppendorf 
tube. Wash pellet as by adding 400 μL of the fractionation buffer to the pellet. 
Resuspend by pipetting. Use a 26 G needle as above. Then re-centrifuge for 45 
minutes. Resuspend the membrane pellet in the same buffer as used for the nuclei. 
10. Store samples at -20oC. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 03:03:55 EET - 137.108.70.7
- 39 - 
 
2.2.9 Protein Analysis 
2.2.9.1 Protein precipitation 
 
2,2,2-Trichloroacetic acid is an analogue of acetic acid firstly synthesized by Jean-
Baptiste Dumas in 1839. TCA-induced protein precipitation is the most popular and 
preferred method for sample preparation regarding proteome analysis [(Nandakumar, 
Cheung et al. 2006); (Jacobs, van Rijssen et al. 2001)]. Protein precipitation with 
TCA is an instantaneous, simple, and efficient process which is also performed to 
remove a buffer or a substance out of the sample of interest, or to concentrate 
samples (e.g. for SDS-PAGE). The mechanism of this method is based on the fact 
that negatively charged trichloroacetate ions trigger protein unfolding by intervening 
with the electrostatic interactions that stabilize the native conformation of proteins. 
This partial unfolding of proteins results in the exposure of solvent-accessible non-
polar surfaces, which consequently results in intermolecular coalescence of protein 
molecules leading ultimately to their precipitation (Rajalingam, Loftis et al. 2009). An 
ideal method for protein extraction should reproducibly capture the most 
comprehensive repertoire of proteins possible, with no or very minimal degradation 
and contamination by non-proteinaceous compounds (Harder, Wildgruber et al. 
1999). The disadvantage of this method is that unfolded/denatured proteins have a 
lower tendency to precipitate in TCA. 
This method was used to precipitate the proteins present in the fractions of 
cytosol, membrane and nucleus, and also to eliminate any reducing substance that 
could interfere with the Lowry assay. The TCA-induced protein precipitation protocol 
is the following: 
1. Add 1 volume of TCA stock to 4 volumes of protein sample. 
    i.e. in 1.5 mL tube, add 250 μL TCA to 1 mL sample. 
2. Incubate for 10 minutes on ice. 
3. Centrifuge tube(s) at 14.000 rpm for 15 minutes at 4oC (Centrifuge 5417R, 
Eppendorf). 
4. Remove carefully the supernatant, leaving protein pellet intact. Pellet should be 
whitish and turbid. 
5. Wash pellet with 200 μL cold acetone. 
6. Centrifuge tube(s) again at 14.000 rpm for 15 minutes at 4oC. 
7. Repeat steps 4-6 for a total of 2 acetone washes. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 03:03:55 EET - 137.108.70.7
- 40 - 
 
8. Dry pellet by placing tube in 95oC heat block (Thermomixer compact, Eppendorf) 
for 8 minutes to drive off acetone. 
9. Add protein buffer (Thunemann, Wen et. al 2013). 
 
2.2.9.1 Protein Quantification 
 
The protein concentration of subcellular components was determined using the 
Peterson’s modification of the Lowry method [(Lowry, Rosebrough et al. 1951); 
(Peterson 1977)]. The Lowry protein assay consists of two reactions: The first one is 
based on the biuret test in which cupric ions bind with peptide bonds of the proteins 
under alkaline conditions (Lowry Reagent Solution). In the second reaction (Folin 
Ciocalteu’s Phenol Reagent Working Solution) which is under acidic conditions, 
electrons are transferred from the cupric ion peptide complex to molybdenum ions 
which are thereafter reduced to molybdenum blue. This blue colored solution can be 
measured photometrically and directly correlates with the protein content of the 
sample. Finally, the protein concentration can be determined using a calibration 
curve. 
The advantage of the Lowry method is the insensitivity to detergents such as 
SDS, which is contained in the lysis buffer and thus in the protein lysates. On the 
other hand, the sample has to be free from any reducing agent, which would disturb 
the Lowry assay. Therefore, it must be performed after TCA precipitation. 
The protein quantification was performed to permit equal loading of protein for 
SDS-PAGE and for Western blot afterwards, to facilitate the comparison of different 
protein samples. The Micro-Lowry-Total-Protein-Kit (Sigma) was used. BSA standard 
controls were prepared and the used concentration was 12.5 μg/mL, 25 μg/mL, 50 
μg/mL, 100 μg/mL, and 200 μg/mL. As a negative control, H2O (milliQ) was used. All 
protein determinations were performed double at room temperature. 
 
1. Add separately in a 96 well plate, 10 μL of protein sample(s) diluted with 90 μL 
H2O and 100 μL of each BSA standard. 
2. Prepare negative controls; 90 μL H2O along with 10 μL of particular lysis buffer in 
which the protein samples are diluted and separately 100 μL H2O. 
5. Add 100 μL Lowry Reagent Solution in each well of interest. 
6. Vortex briefly for 2 seconds and incubate in the dark for 20-30 minutes at room 
temperature.  
7. Add 50 μL of Folin Ciocalteu’s Phenol Reagent Working Solution. 
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8. Vortex briefly for 2 seconds and incubate in the dark for 45 minutes at room 
temperature.  
9. Read absorption at 620 nm in a spectrophotometer (Multiskan EX, Thermo 
Scientific). 
10. Plot the optical density (OD 620) against the BSA concentration, fit a linear 
regression analysis, and calculate the desired concentrations of the protein samples. 
2.2.9.2 SDS-PAGE 
 
The separation of macromolecules in an electric current is called electrophoresis. A 
common method for separating proteins by electrophoresis uses a discontinuous 
polyacrylamide gel as a support medium and sodium dodecyl sulfate (SDS) gel to 
denature the quaternary, tertiary and secondary structure of proteins. The method is 
called sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
(Laemmli 1970). The proteins in SDS-PAGE are separated according to their 
electrophoretic mobility which is dependent on their size. To be specific, the 
negatively charged SDS molecule binds in a ratio of approximately 1 molecule per 2 
amino acids, which leads to a negative charge which is proportional to the unique 
mass of a protein.  
The proteins which are represented in bands can be visualized afterwards via 
coomassie staining. The loading buffer contains β-mercaptoethanol for reducing 
conditions. 
 
2.2.9.2.1 Preparation of Polyacrylamide Gels 
 
The polyacrylamide gels were prepared using the Mini PROTEAN 3 System 
(BioRad). The gels were used in a thickness of 1.5 mm and the recipe is given below 
(Table 2.2). The 8% gels were prepared for the proteins of interest. Gels were 
prepared as following: 
1. Clean glass plates with soap and later with 70% ethanol thoroughly and let dry. 
2. Clamp glass plates in the Mini PROTEAN 3 System rack and test with H2O (milliQ) 
to detect any leakage. In that case, reassemble firmly the glass plates in the rack. 
3. Prepare resolving gel solution, add TEMED and APS lastly. 
4. Pour solution between the glass plates with a pipette facing vertically, up to 
maximum 2 cm beneath the upper rim. 
5. Overlay solution with 1 mL isopropanol and allow polymerization for 20 minutes. 
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6. Remove isopropanol thoroughly and allow the gels to dry. 
7. Prepare stacking gel solution, add TEMED and APS lastly. 
8. Place until top the stacking gel solution and place combs immediately afterwards. 
9. Allow polymerization and wait for 40 minutes. 
10. Remove combs and use the gel or wrap altogether the glass plates with gel and 
comb in a wet tissue paper, and later wrap with cling film to maintain humidity. 
Finally, store at 4oC until future use (approx. up to 1 week). 
 
 
Table 2.2. Composition of polyacrylamide gels. The given amounts are adequate for two 0.75 mm gels. 
A ready-to-use aqueous 30% acrylamide and bisacrylamide stock solution at a ratio of 37.5:1 
(Rotiphorese Gel30, Roth) was used; TEMED (Roth) and APS should be added at last. 
 
Reagents Resolving gel Resolving gel Stacking gel 
 12% 8% 4% 
Rotiphorese 4 mL 2.7 mL 0.65 mL 
4×resolving gel buffer 2.5 mL 2.5 mL - 
4×stacking gel buffer - - 1.25 mL 
TEMED 10 μL 10 μL 10 μL 
APS (20%) 50 μL 50 μL 50 μL 
H2O (milliQ) 3.4 mL 4.7 mL 3.05 mL 
 
 
2.2.9.2.2 Separating proteins through SDS-PAGE gel 
 
1. Add 5x Lämmli SDS loading buffer to the protein samples. 
2. Incubate for 5 minutes at 95oC and centrifuge briefly. 
4. Install gels in the gel running chamber, fill with SDS running buffer, take out 
the comb and wash the loading wells. 
5. Load gels with the supernatant of the protein samples; load 2-5 μg protein per well 
and 3 μL of marker (PageRuler Plus Prestained Protein Ladder, Fermentas). 
6. Start running gel with 100 V until running dye front (bromophenol blue) enters the 
resolving gel, then switch to 150 V. 
7. Stop gel after approx. 40 minutes, when the running dye front runs out. 
8. Disassemble the gel chamber, separate the stacking from the running gel and 
discard the stacking gel. 
9. Use gel for Coomassie staining or for Western blot. 
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2.2.10 Confocal Laser Scanning Microscopy (CLSM) 
 
Confocal microscopy is a powerful tool for visualization and quantification of three-
dimensional structures. The basic concept of confocal microscopy was originally 
developed by Marvin Minsky (Minsky 1961).  Modern confocal microscopes are now 
considered as integrated electronic systems where the optical microscope plays a 
central role in a configuration that consists of one or more electronic detectors, a 
computer (for image display, processing, output and storage), and several laser 
systems combined with wavelength selection devices and a beam scanning 
assembly. These microscopes are now being employed for investigations on 
molecules, cells, and living tissues that were not possible few years ago. 
Confocal microscopy offers several advantages over conventional widefield 
optical microscopy, including the ability to control depth of field, elimination or 
reduction of fluorescence emission from regions removed from the focal plane which 
is the main cause for quality degradation in the image, and the capability to collect 
serial optical sections from thick specimens. The consequent result is the drastical 
improvement of contrast providing enhanced clarity.  
Briefly, the basic tools in a CLSM are the following (Claxton 2006): 
1. Laser  
It is the illumination source which excites the fluorophores of a specimen. It 
can be focused by the lens system to a very small spot at the focal plane. The 
sample can be protected from photobleaching by lowering its intensity. 
2. Scanner 
The image of a specimen can be generated by scanning the focused beam 
across a defined area in a raster pattern controlled by two high-speed 
oscillating mirrors driven with special galvanometer motors. One of the 
mirrors moves the beam from left to right along the x lateral axis, while the 
other translates the beam in the y direction. 
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3. Z-control 
It provides the ability to focus into a specimen and acquire layer images X-Y 
through the z axis, as well as regulation of parameters such as the of size of 
moving step towards the z axis. 
4. Pinhole 
It is a very important tool as it can exclude fluorescence signals from out-of-
focus features positioned above and below the focal plane. It also serves to 
eliminate much of the stray light passing through the optical system. 
5. Photomultiplier (PMT) 
These low-background photomultipliers are able to detect protons which are 
emitted by the reflection of the specimen after illumination. 
6. Dicroic Beam Splitter 
It determines the route of the fluorescent rays and it is determined by a 
combination of basic (HFT) and secondary dicroic mirrors (NFT) and 
excitation filters. 
HFT: separates the excitation light from the emission light, 
NFT: separates the emitted fluorescence; e.g. NFT 545 mirror reflects light in 
wavelength lower than 545 nm and permits the light in wavelength higher 
than 545 nm to pass through.   
7. Objective lens 
It determines the magnification of the specimen, as well as the resolution of 
an acquired image which is dependent upon the light intensity.  
In the current study, CLSM imaging was performed on a Zeiss LSM 510 META, 
with living VSMCs incubated with or without Hoechst 33258 dye (1:250), 1 hour prior 
of the beginning of the experiment. The executed steps were the following: 
1. Mount the coverslips with cells on the stage and use the 63x/1.4 lens which is 
covered on top with a drop of oil (Immersol 518 F, Zeiss), to ensure light 
intensity. 
2. Install the laser and the wavelength of interest (e.g. Argon/2, 488 nm for 
EGFP) and set up the intensity of laser light (5-25%). 
Consider that the laser can cause photo-bleaching of the sample and 
therefore a low intensity should be used.  
3. Excite in the appropriate wavelength and detect a region of interest, via 
epifluorescence.  
4. Select the suitable reflectors and dicroic mirrors (e.g. NFT 490). 
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5. Select “Fast XY” to perform continuous fast scanning, while the “Detector 
Gain” is on and arranged in the range of interest. 
The “Fast XY” is useful for finding and changing the focus. The resolution is 
dependent upon the “Detector Gain”. The latter option determines the 
sensitivity of the detector by setting the maximum limit. 
6. Arrange “Z-stack”. 
7. Select upper/lower focus and arrange “step size”. 
8. Set up other parameters such as the number of slices to increase the signal 
to noise ratio. 
9. Close pinhole to 1 arb. unit, before you start acquiring a confocal image. 
10. Wait a few minutes as the scanning process is running, and later observe and 
save the obtained confocal image. 
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3 Results 
3.1 Immunocytochemistry of transgenic VSMCs from the aorta 
 
VSMCs expressing either cGi500 or mcGi500, were isolated from the aorta of 
transgenic mice (R26-CAG-cGi500 and R26-CAG-mcGi500, respectively) and 
analyzed as a part of this research. Their morphology is clear enough to be observed 
and distinguished in respect to the sensor type, when using 40x magnification in an 
epifluorescence microscope. Considering the 3D structure of a cell, VSMCs 
expressing the cGi500 biosensor can be distinguished from the cells expressing 
mcGi500 by the fact that in the first case, the nucleus is more obvious as the 
fluorescence deriving from the expression of cGi500 sensor, is located to the cytosol, 
whereas in the case of mcGi500, the fluorescence is more dim because the sensor is 
distributed in the membrane and therefore the inner part of the cell is hardly visible.  
VSMCs differ from other types of SMCs such as those from the digestive or the 
urogenital tract, by the fact that α-smooth muscle actin is predominantly expressed in 
VSMCs (Gabbiani, Schmid et al. 1981). It has also been reported that the expression 
levels of this protein, remain in high levels in the contractile state of the VSMC and 
they are reduced during phenotype switch (Rensen, Doevendans et al. 2007). Thus, 
antibody for α-smooth muscle actin can be used as a marker for the detection of 
contractile VSMCs. 
In the following figures, immunofluorescence staining of primary VSMCs 
expressing either cGi500 or mcGi500 is presented. Firstly, immunocytochemistry was 
performed for the detection of α-smooth muscle actin. VSMCs were grown in normal 
cell culture medium (DMEM with 10% FBS) for 8 days and in serum-free medium for 
2 additional days. It was found that 55% of cells deriving from mixed 
mcGi500/cGi500 VSMC culture were α-smooth muscle actin-positive (figure 3.1, A) 
and 59% of mcGi500 VSMC culture were α-smooth muscle actin-positive (figure 3.1, 
B). The proportions come from the average out of 4 calculations in different fields of 
view and are in accordance with previous observations (M. Thunemann). 
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(A)  
(B)  
Figure 3.1. Immunofluorescence for the detection of α-smooth muscle actin in aortic VSMCs 
expressing mcGi500 and cGi500. Primary antibody: monoclonal anti-α (mouse) smooth 
muscle actin. Secondary antibody: Alexa Fluor 555 anti-mouse IgG (H+L) (red), and Hoechst 
33258 for nuclear staining (blue). (A) Representative image of mcGi500- and cGi500-VSMC 
mixed culture. (B) Representative image of mcGi500-VSMC culture. The images were 
obtained at 40x magnification. Scale bars: 35 μm. 
Immunofluorescence staining was also performed for the detection of cGi500 
and mcGi500 by using an anti-GFP antibody, so that we would observe the 
distribution of the fluorescence via epifluorescence microscopy, after the 
immunostaining process (figure 3.2, right side). The endogenous fluorescence of 
both sensors expressed in VSMCs was partially or fully diminished after staining 
(figure 3.2, left side). The percentage of EGFP-positive VSMCs was 100%, as it was 
examined in 5 different fields of view.  
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Figure 3.2. Immunostaining of mcGi500- and cGi500-VSMCs in the absence (left side) and 
presence (right side) of polyclonal anti-GFP primary antibody (rabbit) and secondary Alexa 
Fluor 594 anti-rabbit IgG (H+L) (red). Hoechst 33258 was used for nuclear staining (blue). 
The endogenous fluorescence (green) of sensors (left side) was detected in the YFP channel 
after the immunostaining process. The images were obtained at 40x magnification. Scale 
bars: 35 μm. 
3.2 Localization of mcGi500 and cGi500 in subcellular compartments 
 
The cGMP FRET biosensors mcGi500 and cGi500 may be useful research tools to 
study in real-time the cGMP levels within living cells after application of a specific 
substance. In principle, the mcGi500 biosensor is designed to be localized 
specifically to the membrane, while cGi500 lacks this ability. What makes the 
difference for mcGi500 is the expression of eight additional amino acids (Met-Gly-
Cys-Cys-Phe-Ser-Lys-Thr) from the MARCKS protein (Myristoylated Alanine-Rich 
Protein Kinase C Substrate) that is endogenously localized to the plasma membrane. 
This localization occurs due to hydrophobic interactions of the N-terminal 
myristoyl moiety with the membrane (Manenti et. al 1999). Myristoylation refers to the 
attachment of a C14 saturated fatty acid (myristate) to the N-terminal glycine of 
substrate proteins. The soluble enzyme N-myristoyl transferase transfers a myristoyl 
moiety from the cofactor myristoyl-CoA to the N-terminus of nascent proteins 
containing the consensus sequence (Gly-X-X-X-Ser/Thr) (Johnson et al., 1994). The 
first eight amino acids of the MARCKS protein are essential for this process. The 
myristoyl moiety mediates insertion into the lipid bilayer and thereafter the sensor is 
able to be localized to the membrane. 
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It was a subject of interest to verify if this kind of localization of mcGi500 does 
indeed take place in aortic VSMCs, and also to investigate eventually the exact 
localization of cGi500 in subcellular compartments. For these purposes, two 
strategies were put in application. In the first case, VSMCs expressing each sensor 
had been passaged twice and seeded separately in cell culture dishes (100 mm x 20 
mm, Corning), until they reached at least 80% confluency. Then, subcellular 
fractionation was performed, and the obtained fractions for the nucleus, the cytosol, 
and the membrane were destined for Western blot analysis. The basic idea was to 
use for every fraction, antibodies that detect proteins embedded in the membrane, 
antibodies for the detection of proteins in the cytosol and EGFP antibodies which 
detect the cGi-type biosensors. Then, the results would provide important information 
about the localization of each sensor.  
Preceding Western, protein analysis of the samples for the different fractions 
had to be performed. The TCA protein precipitation method was performed to 
remove the reagent DTT that was present in the buffer of samples, and to 
concentrate them. Lowry assay was performed and the results showed that the 
concentration of proteins in the membranic and nuclear fraction was considerably low 
(~ 0.03, 0.025 mg/mL respectively), while the concentration of the cytosolic one was 
normal (~ 0.2 mg/mL). SDS-PAGE and Coomassie staining were performed and 
from the results which are shown below (figure 3.3), we would decide if it was 
feasible to continue with the Western blotting assay. Finally, the experiment was 
recommended to end at that point, without proceeding with Western blotting, as the 
membranic and the nuclear fraction reported absent or very weak signal, after SDS-
PAGE and staining with Coomassie. 
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Figure 3.3. Coomassie stained polyacrylamide gel (8%) after SDS-PAGE protein separation 
of fractions deriving from the cytosol, the membrane, and the nucleus of aortic VSMCs 
expressing either mcGi500 or cGi500 biosensor. “1:10” represents the dilution of the samples 
with loading buffer and “M” stands for the pre-stained molecular weight marker. 
In the meantime, there was also another strategy that seemed more direct 
and promising than the previous one. This was to obtain images of living cells by 
confocal microscopy, to observe in depth the fluorescence of each biosensor and 
therefore draw safe conclusions about its distribution. The primary advantage of laser 
scanning confocal microscopy over epifluorescence microscopy is the ability to 
produce thin (0.5 to 1.5 μm) optical sections through fluorescent specimens. A set of 
two-dimensional (2D) confocal images that were obtained sequentially inside the 
specimen, were combined and resulted in a three-dimensional (3D) fluorescent 
image of the cell (figure 3.5). 
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Figure 3.4. Images of living VSMCs obtained with confocal laser scanning microscopy. (A) 
VSMCs expressing the membrane-bound mcGi500 (left) and cytosolic cGi500 (right) 
biosensor. (B) VSMC expressing the mcGi500 biosensor; the nucleus and vesicles that were 
transporting mcGi500 protein molecules to the membrane, can be observed. (C) VSMCs 
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expressing mcGi500 sensor, pre-incubated with Hoechst 33258 for nuclear staining (blue). 
The images were obtained at 64x magnification. Scale bars: 35 μm.    
From the results (figures 3.4, 3.5), it was made obvious that mcGi500 was 
located indeed in the membrane; for instance, the cross-section below (figure 3.5) 
indicates that the fluorescence of the sensor (i.e. mcGi500 localization) is almost 
absent inside the VSMC. In contrast, the fluorescence deriving from cGi500 was 
found to be located in the cytosol in much higher levels than mcGi500. cGi500 
expression was observed also in the nucleus, but at lower levels than in the cytosol.  
 
Figure 3.5. Confocal 3D image of aortic VSMCs expressing mcGi500 (left) and cGi500 (right). 
The white line indicates the performed cross-section, and at the bottom there is the result of 
the section as it is observed from the side of the cells. It is also illustrated the orientation of 
the specimen in respect to x,y and z axis (right side). The ultimate height of the VSMC (right) 
onto the coverslip was found to be 6 μm. 
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3.3 General responses of VSMCs from the aorta, to ANP, CNP & DEA/NO  
 
In general, aortic VSMCs express both GC-A and GC-B receptors, as well as the 
sGC receptor. ANP, CNP and the nitric oxide donor DEA/NO were used as part of 
this research, to activate the catalytic domain of those receptors, respectively. 
Examining how the aortic VSMCs respond to each activator is an important aspect of 
this study. 
The responses of primary VSMCs from the aorta, after ANP, CNP, and 
DEA/NO application, were measured in living cells and in real-time, by utilizing the 
FRET principle. Either of two biosensors was expressed in these cells: the cGi500 
which is predominantly expressed in the cytosol and the mcGi500 which is a 
membrane-bound biosensor. The responses are presented as curve formations, 
which depict the change of CFP/YFP ratio relative to the baseline (ΔR/R). 
After FRET experiments, the results were evaluated via Excel and Origin. The 
two evaluation strategies were performed to compare the calculated results with each 
other, and then select the most accurate parameters for the comparison of the 
cGi500 and mcGi500 sensors. One method seemed to overlap the weaknesses of 
the other. Paradigm of a positive correlation between the two methods of evaluation 
is depicted below (figure 3.6). Finally, the selected parameters presented in this 
study, were “a”, “c”, and “h” parameters from Excel, as well as the “p” parameter 
calculated via Origin.    
 
Figure 3.6. Comparison between peak height “h” (y axis) and “span” (x axis) parameters from 
the same measurement, as they were calculated via Excel and Origin, respectively. The 
illustrated R2 value indicates a close correlation between the calculated parameters.    
Results from the data evaluation demonstrated that VSMCs do not respond in 
the same manner for each cGMP-elevating agent (ANP, CNP or DEA/NO). To be 
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specific, cells exhibited weak, mild, strong, or even absent responses after 
application of ANP (figure 3.7). The same phenomenon was observed also for CNP. 
What is more, absent responses seem to be independent of the drug concentration 
(figure 3.8). In contrast, responses to DEA/NO were predominantly strong and only a 
minority (5%) of the examined VSMCs did not respond; specifically, only 6 out of 120 
examined cells, in 17 relative experiments, did not react to DEA/NO. However, even 
if most of the DEA/NO responses were strong, there was not a particular pattern in 
the kinetics and the shape of the respective curves in all cases (figure 3.9).  
 
 
Figure 3.7. Representative examples of the variability in the strength of FRET cGMP 
responses in VSMCs, after ANP application: (A) strong , (B) mild, (C) weak, and (D) absent 
responses. The concentations of ANP which were used are the following: (A), (B) 85 nM, (C) 
170 nM and (D) 100 nM. The examples derive from responses of cGi500-expressing VSMCs. 
The grey rectangles indicate the drug application.  
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Figure 3.8. Absence of response in elevating concentrations of CNP, regarding a single 
VSMC (sensor: mcGi500). The grey bars indicate the application of CNP, in the order of 
following concentrations: 16, 33, 50 & 75 nM. The green bar indicates the induced response 
to DEA/NO (100 nM). 
 
 
                                                                                        
 
Figure 3.9.   Diversity in curve shape and kinetics between aortic VSMCs regarding DEA/NO 
responses in a representative experiment. The three curves (upper side) stem from 
responses of 3 different VSMCs to DEA/NO (100 nM) in the same experiment; (A), (B) 
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mcGi500, and (C) cGi500 are the expressed cGMP FRET biosensors. The grey rectangles 
indicate the drug application. The studied “p” parameter (lower graph) represents the rise of 
each curve, as it was calculated via Origin.  
In dose-response experiments, aortic VSMCs exhibited a different behavior 
after being exposed to elevating concentrations of ANP, CNP and DEA/NO. This 
behavior can be easily distinguished and compared by eye (figure 3.10). VSMCs 
responded generally stronger to each rising concentration of CNP (figure 3.10, B). 
However, the same phenomenon was not observed for the VSMCs which had been 
stimulated and reacted to ANP in another relative experiment (figure 3.10, A). Finally, 
the cells which were treated in rising concentrations of DEA/NO displayed an acute 
response already at the initial drug application and it seemed that there was only a 
slight change in the characteristics of the curves in-between the various drug 
applications (figure 3.10, C). However, the examination of the data of the latter 
experiment demonstrated increases in the p parameter of those curves, as the 
DEA/NO concentration was rising (figure 3.11).  
 
 
Figure 3.10. Dose-response experiments in aortic VSMCs (sensor: cGi500) applying ANP 
(A), CNP (B) and DEA/NO (C). The performed number of experiments is: (A) 1, (B) 3 and (C) 
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2; the number of VSMCs that are represented by this behavior of curves are: (A) 3, (B) 7 and 
(C) 18. The concentrations for each cGMP-modulating agent are the following: ANP: 85, 170, 
210 nM, CNP: 16, 33, 50, 75 nM and DEA/NO: 33, 50, 80, 100, 200 nM. The grey rectangles 
indicate the respective drug application.  
                           
Figure 3.11. Graph depicting elevating p-values (y axis) in a representative DEA/NO dose-
response experiment. The illustrated curves are associated with responses deriving from 6 
representative VSMCs (3 for each of both cGi-type FRET sensors). The DEA/NO 
concentrations were calculated in the logarithm of 10 and are the following: 33, 50, 80, 100, 
200 nM.  
The aortic VSMCs as mentioned above, do not behave equally and most 
importantly it seems that there is a division into distinguished categories in the 
examined cell type. These “subpopulations” consist of three kinds at least: The aortic 
VSMCs which respond to CNP but much less intense to ANP and vice versa 
(example, figure 3.12, A), VSMCs which barely respond to CNP but they do respond 
after DEA/NO application (figure 3.12, B) and last but not least, VSMCs which 
respond to CNP but they cannot receive the cGMP-elevating stimulus after addition 
of DEA/NO (figure 3.12, C) 
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Figure 3.12. Differential FRET cGMP responses between aortic VSMCs, after serial 
applications of cGMP-modulating agents (ANP, CNP & DEA/NO) in rising concentrations. (A) 
Strong response to CNP and weak reaction to ANP; sensor: mcGi500. (B) Weak responses to 
CNP and strong reactions to DEA/NO; sensor cGi500. (C) Strong responses to CNP and 
weak-absent responses to DEA/NO; sensor: mcGi500. The grey rectangles indicate the 
respective drug application.  
The results also demonstrated that in the case of CNP, there was a decrease 
in the time until response (“a” parameter) of aortic VSMCs between the first and 
second application (figure 3.13). The fact that cannot be excluded though, is that the 
two applications differed in concentration, with the latter being higher than the formal 
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one. For this reason, it was considered to perform again FRET measurements, 
applying this time the same concentration of CNP in order to investigate if it was 
really an effect of the concentration. From the new results it seems that there is such 
dependency, but a certain consensus cannot be drawn since there were cases in 
which VSMCs still reacted faster in the second application of the same concentration 
of CNP (figure 3.14).  
 
Figure 3.13. Difference in time (s) between the 2nd and 1st response (Δa) after CNP 
applications ([CNP]2nd>[CNP]1st), in aortic VSMCs expressing mcGi500 (14 cells) and cGi500 
(9 cells). All VMSCs (apart from 1) demonstrate a faster CNP response (Δa<0). The box-plot 
refers to results deriving from 6 representative experiments. 
                                                          
Figure 3.14. Difference in time (s) between the 2nd and 1st response (Δa) after applications of 
the same concentration of CNP in aortic VSMCs expressing the FRET cGMP biosensors 
mcGi500 (8 cells) and cGi500 (7 cells): VSMCs demonstrate a slower or unchanged (Δa≥0) 
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and a faster 2nd CNP response (Δa<0). The box-plot refers to representative examples of 3 
relative experiments. 
However what is clear from the latter experiments, is that there is a tendency 
for decrease in another important parameter: the height (h) of the curves, which 
represents the strength of each cGMP response within the VSMC. It was observed 
that this decrease through applications of the same concentration of CNP, occurred 
only conditionally: The aortic VSMCs which reacted relatively weakly to the first 
concentration of CNP and produced a FRET curve below or equal 0.1 ΔR/R, they 
could increase the peak height of their curves and therefore have a second stronger 
response to the same concentration of CNP (figure 3.15, A). In contrast, in VSMCs 
which firstly reacted over 0.1 ΔR/R (constituted the majority of cells), the height of 
their second FRET curve after application of the same dose of CNP was decreased 
in most cases or stayed in the same level (figure 3.15, B). Exceeding the second 
application of CNP while maintaining its concentration, the height of curves was 
ultimately reduced for every VSMC.  
 
Figure 3.15. Differences in peak height (h, ΔR/R) of the responses between repetitive 
applications of the same concentration of CNP in aortic VSMCs: (A) 1st response of VSMCs, 
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below or equal of 0.1 ΔR/R, and (B) 1st response of VSMCs, over 0.1 ΔR/R. All the examined 
VSMCs demonstrate a decreasing tendency in the strength of their responses, after repetitive 
CNP applications with the same concentration. These graphs depict representative examples 
of 3 relative experiments. 
    
3.4 Comparison of cGi500 and mcGi500 biosensors in aortic VSMCs 
 
The FRET biosensors cGi500 and mcGi500 differ in localization as the cGi500 is 
located predominantly in the cytosol, while mcGi500 is located to the membrane. 
Hence, cells expressing these sensors may also differ in speed and intensity of 
FRET responses after receiving cGMP-elevating stimuli in the plasma membrane or 
in the cytosol via pGC and sGC receptors, respectively. In order to compare and 
contrast these biosensors, mixed cell cultures of primary VSMCs expressing the 
sensors were grown onto 13-mm coverslips of 24-well plates in normal cell culture 
medium (DMEM with 10% FBS). One day or two days prior FRET analysis, the 
medium was changed to be serum-free. The analyzed aortic VSMCs derived from 
four different batches of heterozygous transgenic mice (R26-CAG-mcGi500 and R26-
CAG-cGi500).  
Although isolated from different mice, mixed cell cultures provide the 
opportunity to analyze distinct VSMCs expressing either sensor, in the same field of 
view, at the same time, and under the same cell culture and imaging conditions. The 
amount of the examined aortic VSMCs for the comparison of the sensors, the days in 
vitro, and the experimental design in respect with the selected drug applications are 
depicted below (figure 3.16). The total number of examined VSMCs was 75 for 
cGi500 and 93 for mcGi500, while 10 VSMCs expressing mcGi500 that exhibited too 
much noise during FRET measurements, and 2 VSMCs that could not be identified 
regarding sensor expression, were excluded from the evaluation. Generally, 
mcGi500 exhibited more noise than cGi500 (figure 3.17).  
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Figure 3.16. (A) Total number of examined VSMCs depicted in ROIs (B) days in cell culture 
(in vitro), (C) experimental design. 
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Figure 3.17. Box-plot depicting the standard deviation of baseline mean between cGi500- 
and mcGi500-expressing VSMCs (25 and 34 in number, respectively). Each dot represents a 
single VSMC and its respective value. The closer the value to 0%, the less noise is present. 
CNP binds preferentially to the GC-B receptor which is located in the plasma 
membrane (Koller and Goeddel 1992). Therefore, experiments applying CNP as a 
cGMP-modulating agent would reveal if there are indeed differences between the 
VSMCs expressing mcGi500 and cGi500 regarding parameters which reflect for 
instance, the strength and speed of cGMP-FRET responses. DEA/NO was used as 
well, for this kind of comparison. The generated NO induces cGMP production 
through the sGC which is considered to be located in the cytosolic compartment 
(Mayer, Schmidt et al. 1989). Regarding the experimental design, CNP was either 
applied exclusively or before application of DEA/NO (figure 3.16, C). 
3.4.1 CNP 
 
For the comparison, many parameters regarding the curve of each response have 
been calculated, in order to detect the differences and elucidate partially into the 
cGMP-patterns after drug application. One crucial parameter is the peak height (h, 
ΔR/R) of the cGMP transient from the baseline, which indicates the strength of the 
cGMP response.  
Regarding the CNP (50 nM) application, it was observed from a total of 12 
experiments that 34% of VSMCs expressing cGi500 reacted weakly (“0-0.15 ΔR/R”), 
whereas the respective percentage for VSMCs expressing the mcGi500 biosensor 
was only 5%. In contrast, 81% of VSMCs expressing the membrane-bound biosensor 
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reacted relatively strongly, while only 49% of VSMCs expressing the cGi500 reacted 
similarly (figure 3.18, A).   
As far as the CNP (100 nM) application is concerned, the percentage of 
VSMCs which reacted weakly was 3% for the mcGi500 and 31% for cGi500. 
Moreover, cells that reacted over 0.15% ΔR/R occurred more frequent for mcGi500 
(90%) in comparison with the cGi500 biosensor (48%) (figure 3.18, B).  
 
 
Figure 3.18. Comparative graphs depicting the strength of cGMP responses, as indicated by 
the height (h, ΔR/R) of the respective curves from VSMCs expressing either mcGi500 or 
cGi500 biosensor. “0 ΔR/R” indicates absent responses, “0-0.15 ΔR/R” weak and “>0.15 
ΔR/R” mild-strong responses. (A) CNP 50 nM applications; 58 and 41 VSMCs out of 12 
experiments were compared for mcGi500 and cGi500 biosensors, respectively. (B) CNP 100 
nM applications; 31 and 29 VSMCs out of 10 experiments were compared for mcGi500 and 
cGi500 biosensors, respectively.  
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          Apart from the “h” parameter, the rise (“p” parameter) of the curve is another 
important element to study possible differential responses among VSMCs expressing 
different sensors. It was observed in normalized p parameter values to DEA/NO (100 
nM) that there are such dissimilarities, regarding the responses in various CNP 
concentrations (figure 3.19). The higher the p parameter, the more rapid and intense 
the cGMP increase is. According to these representative graphs, transgenic VSMCs 
which express the mcGi500 biosensor receive in general, more acutely the CNP-
induced cGMP generating FRET-signal than those with the cGi500 biosensor. 
                                                                            .                                       
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Figure 3.19. Representative examples out of 3 different experiments indicating the rise of 
cGMP transients (“p” parameter), after CNP applications, in VSMCs expressing mcGi500 and 
cGi500. Values of “p” parameter were normalized to DEA/NO (100 nM; p=1), and calculated 
as for: (A), (B) CNP (50, 100 nM), DEA/NO (50 nM), and (C) CNP (33, 50, 75 nM).  
3.4.2  DEA/NO 
 
As far as the DEA/NO applications are concerned, the parameters which were taken 
into consideration for the comparison of mcGi500 and cGi500 biosensors, were “a” 
and “c”. The “a” parameter refers to the time of the drug application until a sufficient 
cGMP level is reached, which would indicate the time of response. As depicted in 
figure 3.20, the VSMCs expressing the two sensors differ only slightly in respect to 
this parameter. Furthermore, the two types of transgenic aortic VSMCs demonstrate 
also similarities after DEA/NO application, in relation with the “c” parameter which 
represents the time of application until the time in which the curve reaches its 
maximum (figure 3.21).  
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Figure 3.20. Box-plot associated with the time (s) of DEA/NO application until response (“a” 
parameter) of cGi500- and mcGi500-expressing VSMCs from the aorta. Each dot represents 
one single VSMC and its respective value of “a” parameter; 17 cGi500 and 27 mcGi500-
expressing VSMCs were analyzed out of 5 experiments. 
                                                        
Figure 3.21. Box-plot regarding the time (s) of DEA/NO application until cGMP transient 
reaches its maximum (“c” parameter) between VSMCs from the aorta expressing cGi500 and 
mcGi500. Each dot represents a VSMC and its respective value of “c” parameter; 22 cGi500 
and 31 mcGi500-expressing VSMCs were analyzed out of 6 experiments. 
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3.4.3 CNP versus DEA/NO 
 
The cGMP signals that are exerted via two different pathways (CNP/GC-B and 
NO/sGC) were found to differ in the kinetics of the FRET curves. For instance in 
regard with the mcGi500 biosensor, the time of response after the first CNP 
application is higher than the respective time frame after the first DEA/NO addition 
(figure 3.22). Moreover, there are also differences in the rise of CNP- and DEA/NO-
mediated cGMP transients (figure 3.19, A,B).  
 
Figure 3.22. Differences in “a” parameter between first applications of CNP and DEANO in 
VSMCs expressing the membrane-bound mcGi500 biosensor. Each dot represents a single 
cell and its respective value of “a” parameter; 19 mcGi500-expressing VSMCs were analyzed 
for DEA/NO and 19 ones for CNP out of 4 relative experiments. 
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3.5 In vitro test for Cre-mediated induction of mcGi500 in smooth muscle 
cells (SMCs) from R26-CAG-mT/mcGi500 mice 
 
R26-CAG-mT/mcGi500 transgenic mice carry a “loxP-silenced” mcGi500 transgene. 
These mice possess two loxP sites on either side of a membrane-targeted tdTomato 
(mT) cassette and show red fluorescence in all cell types examined. When bred to 
mice expressing Cre recombinase, the resulting offspring have the mT cassette 
deleted in Cre-expressing tissue(s) and one loxP site is now left, allowing expression 
of mcGi500 membrane-bound biosensor only in tissues/cell types of interest. 
In this study, vascular, bladder, and colon smooth muscle cells (VSMCs, 
BSMCs, and CSMCs, respectively) were isolated from R26-CAG-mT/mcGi500 
transgenic mice. It was tested whether Cre could induce the expression of mcGi500 
in vitro. Furthermore, it was also tested whether the cGMP levels of those 
recombined cells could be monitored in real-time in FRET microscopy. The figure 
illustrated below prove that Cre-mediated excision is indeed achievable in vitro via 
protein transduction with HTNC: recombined cells expressing the mcGi500 FRET 
biosensor appear in color “green” (figure 3.23). 
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Figure 3.23. HTNC protein transduction in primary VSMCs from the aorta (A), BSMCs (B) 
and CSMCs (C) isolated from R26-CAG-mT/mcGi500 mice. The pictures on the left were 
obtained in 20x magnification, right before protein transduction, the 4th day after tissue 
isolation. The pictures on the right were obtained in 40x (A) and 64x (B, C) magnifications via 
epifluorescence microscopy (YFP and CFP channels), the day after protein transduction. 
Recombined SMCs are shown in green color, while non-recombined SMC appear in red. Note 
that the recombined VSMCs which appear in orange color, have not occurred by green and 
red cell overlay. Most probably they express mcGi500, but in the protein level, the expression 
of the “green” mcGi500 is low enough to prevail over the “red” mT. Scale bars: 35 μm. 
Additionally, two days after protein transduction, FRET measurements were 
performed for each cell type expressing mcGi500. Aortic VSMCs were successfully 
monitored in respect to cGMP production, after stimulation with elevating 
concentrations of CNP and DEA/NO (figure 3.24). On the other hand, there were 
poor results for CSMCs and BSMCs as they seemed to be quite sensitive to 
photobleaching or to the imaging procedure, after the stress they had underwent 
through protein transduction. 
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Figure 3.24. cGMP monitoring in dose-response experiments regarding: CNP (A) and 
DEA/NO (B) in HTNC-treated aortic VSMCs isolated from R26-CAG-mT/mcGi500 mice. The 
concentrations used for CNP dose-response experiment are: 50, 75 & 100 nM; for DEA/NO: 
100, 150, 200, 250, 500 nM and lastly applied CNP 100 nM. Red bars represent CNP, while 
blue bars indicate DEA/NO applications. 
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4 Discussion 
4.1 Compartmentalization of cGMP signals in VSMCs from the aorta 
 
Recent studies have revealed that increases in cGMP levels triggered by NPs and 
NO donors lead to regulation of different cellular targets and procedures [(Zolle, 
Lawrie et al. 2000); (Rho, Perkins et al. 2002); (Zhang, Moalem et al. 2005)]. One 
model that explains the differential regulation of cellular processes such as growth, is 
the compartmentalization of cGMP-based cellular signaling (Piggott, Hassell et al. 
2006). Therefore, cGMP signals may be compartmentalized or localized to distinct 
regions of the cell. 
In this study, CNP and DEA/NO were used for the comparison of murine 
VSMCs from the aorta expressing either the mcGi500 membrane-bound biosensor or 
the cGi500 biosensor which is localized in the cytosol. One major obstacle in 
detecting the differences among them, was the genetic diversity that was present 
between the VSMCs deriving from the aortae of mice with different genome. Apart 
from that, differences in the phenotype of VSMCs, as indicated by the expression of 
a-smooth muscle actin, must have also contributed to this obstacle. However, our 
approach of seeding, growing, and then analyzing cGi500- and mcGi500-expressing 
VSMCs together, was to reduce as much as possible, any differences caused by 
preparation and culture. An issue that caused difficulties in the evaluation process, 
was the baseline noise that was mainly present in VSMCs expressing the mcGi500 
biosensor. This noise was most probably correlated with the difference in brightness 
between the two sensors. The baseline noise could not be avoided as there was a 
compromise between photo-bleaching and illumination time. Consequently, some 
cells that were too noisy had to be excluded from the evaluation. Anyhow, the 
number of evaluated VSMCs which expressed the mcGi500 sensor prevailed 
eventually over the number of cGi500-expressing cells.  
Despite all the mentioned impediments, results from the current study show 
that there are differential responses in mcGi500- and cGi500-expressing VSMCs 
after application of CNP. In total, CNP exerted stronger cGMP-FRET signals in 
VSMCs expressing mcGi500 than those with cGi500, as measured by two different 
parameters and evaluation strategies (“h” and “p” for Excel and Origin, respectively). 
Furthermore, the aortic VSMCs which responded weakly to this stimulus were much 
less in number for mcGi500 than for cGi500. This fact implies that CNP induces 
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cGMP production in the membranic fraction, but the generated cGMP may also 
spread and thereafter be detected in other regions within the cytosol.  
As far as the DEA/NO applications are concerned, only slight differences 
were observed between VSMCs expressing the membrane-bound mcGi500 and 
those expressing the cytosolic cGi500 biosensor. These results are consistent with 
the literature as there are researches which prove that sGC which is the only proven 
receptor of NO to date, may translocate in the membranic fraction in some types of 
cells [(Zabel, Kleinschnitz et al. 2002); (Tsai, Liu et al. 2012)]. However, different 
types of experiments should be done to verify that this phenomenon does occur in 
the aortic VSMCs as well. Another intriguing possibility is that sGCs can be present 
in the cytosolic fraction but also very close to the membrane, so that the generated 
cGMP would be detected equally and simultaneously by both biosensors.           
4.2 Mechanisms of receptor regulation 
 
What was also evident from our results, is that there are differences in the kinetics of 
the cGMP transients of VSMCs upon CNP versus DEA/NO application. To be 
specific, the time from drug application until detectable response (i.e. cGMP 
production to a level of ~50-100 nM; Thunemann, Fomin et. al 2013) was lower for 
DEA/NO in comparison with CNP for both biosensors. Moreover, there were 
differences in the “p” parameter of the respective FRET curves, with the values of 
DEA/NO being always higher than for CNP, for both cGi500- and mcGi500-
expressing VSMCs. These results indicate that there must be different regulation and 
activation mechanisms for the sGC and GC-B receptors within VSMCs from the 
aorta. DEA/NO induces faster cGMP production than CNP does. One possible 
explanation for this difference is that time of activation of the catalytic domain after 
ligand binding may be less for the sGC/Fe2+/NO than the GC-B/CNP complex. 
Moreover, it could be also that there is a different catalytic speed of cGMP 
generation, dependent upon the amount of the sGC and GC-B enzymes present in 
VSMCs.     
Experiments in which CNP was applied several times using the same 
concentration, exhibited also some interesting results. It was observed that at the end 
of the repetitive CNP application series, there was a decrease in the monitored 
cGMP levels produced within the VSMC compared to initial application(s) with the 
maximal cGMP levels as shown by the “h” parameter (ΔR/R). This phenomenon is 
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most probably attributed to the model of homologous desensitization of the GC-B 
receptor (Potter and Garbers 1992). Considering this model and the obtained results, 
it seems that there is an initial limit above which a receptor can be desensitized (0.1 
ΔR/R). This observation implies that there is not always complete reduction in the 
phosphate content of the GC-B receptor after first CNP binding, so that the receptor 
would be fully desensitized. In contrast, upon first weak cGMP response that was 
below or equal of 0.1 ΔR/R, the GC-B receptor seemed to be sensitized or at least 
capable of producing higher cGMP levels upon second application of the same 
concentration of CNP. On the other hand, when the first cGMP response exceeded 
the limit which was above or equal of 0.12 ΔR/R, then the following cGMP responses 
were always less intense, indicating receptor desensitization. The reason why this 
phenomenon occurs conditionally, is not clear and further experiments should be 
performed to determine if or/and how this mechanism occurs in vivo.   
From dose-response experiments applying ANP or CNP, it was shown that 
there are dissimilarities in the responses in elevating concentrations of the activators 
of GC-A and GC-B, respectively. Specifically, even if the concentration used in 
second application of ANP was 2-fold higher than the first one, there was a decrease 
in the strength of the second response compared to the formal one. Similarly, the 
next application which was close to 3-fold higher than the formal one, produced an 
even lower cGMP transient. This phenomenon was not present in CNP dose- 
response experiments. These results hint at a different rate of desensitization 
between the two kinds of pGCs in aortic VSMCs. However, facts that cannot be 
excluded are that the concentrations used in these experiments were not equal and 
plus, the number of experiments in which ANP was used, was considerably low due 
to availability issues. Therefore, more FRET measurements should be performed in 
order to verify the upper conclusion. 
4.3 Differential cGMP responses induced by activators of pGC and sGC 
Receptors in VSMCs from the aorta 
 
In this study, aortic VSMCs were found to behave unequally in cGMP-modulating 
factors such as CNP, ANP, and DEA/NO. For instance, a cell that was responsive to 
CNP did not receive such strong cGMP-elevating stimulus induced by ANP and vice 
versa. The same was observed between CNP and DEA/NO, even if reaction to CNP 
and not to DEA/NO happened most rarely. Hence, it was reasonable to consider that 
there is a categorization within aortic VSMCs, in respect to the differential responses 
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to NPs or/and DEA/NO. Below there are models which would try to provide a logical 
interpretation for this divisive phenomenon. 
4.3.1 In vivo 
 
One possibility that might occur in vivo, is that there are mechanisms of synergistic 
cooperation between the VSMCs in the aorta. It could be that this cooperation is 
evolutionarily developed in order to provide balance among the cGMP responses that 
are induced by different modulating agents. What is also possible is that these 
subpopulations of VSMCs exist, because they belong to distinct domains of the aorta 
which is the largest blood vessel in the body. For example, a VSMC derived from the 
aortic arch region may not behave similarly with another one from the subdominal 
aorta, in respect to cGMP signaling mediated by different factors such as ANP and 
CNP. 
Another hypothesis is that aortic VSMCs are genetically pre-disposed to 
abnormal phenotype later in life, fact that might be the onset of aortic pathogenesis. 
For instance, if at any time a spontaneous, but harmful somatic mutation or other 
epigenetic event (e.g. methylation) occurs in the gene encoding for GC-B receptor of 
a VSMC which happens to be unresponsive to ANP already, then the consequent 
result would be that this impaired cell would not be able to receive a cGMP-elevating 
stimulus via the pGC pathway.  
A pessimistic model to justify why these subpopulations occur within the 
same cell type, is that the integration of a gene encoding an artificial FRET biosensor 
in the genome (i.e. the ROSA26 locus) interferes with the native gene expression 
profile of mice. Even if this might occur to some extent, it is probably unlikely that the 
expression of the genes encoding for the pGC and sGC receptors is particularly 
affected. However, experiments need to confirm that there is not such interference. 
4.3.2 In vitro 
 
Taken into consideration that all the presented results stem from experiments in cell 
culture, one might believe that this categorization of aortic VSMCs may possibly not 
exist in vivo, as a change of the endogenous gene expression may happen in vitro. A 
loss of original gene expression might occur due to change of normal 
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microenvironment (ex vivo effect), cell culture conditions (media), and passaging. 
This view is highly acceptable, but it is also worthy to be mentioned that the results of 
this study derive from primary VSMC cultures mostly in passage 0, and cells were 
analyzed within two weeks after tissue isolation. Last but not least, it has been 
proposed that primary VSMCs cultured in vitro, undergo changes similar to those 
observed in neo-intimal VSMCs including decreased expression of specific genes 
and phenotypic switch [(Boerth, Dey et al. 1997); (Lincoln, Wu et al. 2006)]. Hence, it 
could also be the model of in vitro mimicking in vivo pathogenesis.        
4.5 Outlook 
 
In this study, it was revealed that aortic VSMCs exhibit a diversity in response to 
cGMP-elevating factors. This observation is in line with colleagues’ results obtained 
with the same method (Lehners, Thunemann; unpublished). Moreover, it was shown 
that mcGi500 and cGi500 cGMP biosensors show a different subcellular localization. 
Dissimilarities were also exhibited regarding at least the responses upon CNP 
stimulation, while only slight differences were observed after DEA/NO application. 
What is more, the subcellular cGMP pools can be visualized but only partially, by 
utilizing the FRET principle in living cells expressing these sensors. All experiments 
mentioned above can be proved useful for our understanding of the spatiotemporal 
dynamics and the compartmentalization of cGMP signals inside VSMCs.  
In the future, there are important experiments that should be conducted, apart 
from those suggested above. It seems to be that there is a high complexity in cGMP 
signaling via NPs and NO. Thus, the identification of the biochemical events that 
mediate the various effects of these molecules could provide novel targets for 
treatment of conditions including aortic pathogenesis, where intracellular cGMP 
compartmentalization may play an important role. The biosensors examined in the 
current study could be exploited in disease models to investigate possible effects in 
the normal compartmentalization of cGMP and its signaling pathways. A challenging 
concept for the study of subcellular cGMP pools would be to generate transgenic 
mice whose cells express biosensors in specific cellular microdomains such as in 
mitochondria, peroxisomes, and in the sarcoplasmic/endoplasmic reticulum. A variety 
of differentially localized FRET biosensors that could be used and detected at 
different wavelengths, at the same time would be invaluable for this kind of research. 
Even if this would be difficult to be achieved, mainly due to genetic manipulation 
constraints, it would provide the chance for researchers to penetrate into the 
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architecture of the cGMP signaling compartments in a plethora of cell types, in 
physiological and pathological conditions. 
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